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ABSTRACT 
The hen’s egg is a source of new life. Therefore, it contains many biologically 
active compounds. In addition to being a very nutritious food and also 
commonly used in the food industry due to its many techno-functional 
properties, the egg can serve as a source of compounds used as nutra-, pharma- 
and cosmeceuticals. One such interesting compound is ovomucin, an egg white 
protein responsible for the gel-like properties of thick egg white. Previous 
studies have indicated that ovomucin and ovomucin-derived peptides have 
several different bioactive properties. 
The objectives of the present study were to develop isolation methods for 
ovomucin, to characterize the structure of ovomucin, to compare various egg 
fractions as sources of ovomucin, to study the effects of various dissolving 
methods for ovomucin, and to investigate the bioactive properties of ovomucin 
and ovomucin-derived peptides.  
A simple and rapid method for crude ovomucin separation was developed. 
By using this method crude ovomucin was isolated within hours, compared to 
the 1-2 days (including a dialysis step) needed when using several other 
methods. Structural characterization revealed that ovomucin is composed of 
two subunits, α- and β-ovomucin, as egg white protein formerly called α1-
ovomucin seemed to be ovostatin. However, it might be possible that ovostatin 
is associated within β- and α-ovomucin. This interaction could even have some 
effect on the physical nature of various egg white layers.  
Although filtration by-product fraction was a very prominent source of both 
crude and β-ovomucin, process development has reduced its amount so 
significantly that it has no practical meaning anymore. Thus, the commercial 
liquid egg white is probably the best option, especially if it generally contains 
amounts of β-ovomucin as high as were found in these studies. Crude 
ovomucin was dissolved both by using physical and enzymic methods. 
Although sonication was the most effective physical method for ovomucin 
solubilisation, colloid milling seemed to be a very promising alternative. A 
milk-like, smooth and opaque crude ovomucin suspension was attained by 
using a colloid mill.  
The dissolved ovomucin fractions were further tested for bioactive 
properties, and it was found that three dissolving methods tested produced 
moderate antiviral activity against Newcastle disease virus, namely colloid 
milling, enzymatic hydrolysis and a combination of sonicaton and enzymatic 
hydrolysis. Moreover, trypsin-digested crude ovomucin was found to have 
moderate antiviral activity against avian influenza virus: both subtype H5 and 
H7.  
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SUOMENKIELINEN ABSTRAKTI 
Kananmuna on yksi monikäyttöisimmistä elintarvikkeista. Sen lisäksi, että se 
on ravintoainekoostumukseltaan rikas elintarvike, sen toiminnallisia 
ominaisuuksia hyödynnetään elintarviketeollisuudessa laajalti. Muniessaan 
kana ei kuitenkaan pyri tuottamaan erinomaista ihmisravintoa, vaan sen 
tarkoituksena on uuden elämän, kananpojan, synnyttäminen. Tämän vuoksi 
kananmuna sisältää monia biologisesti aktiivisia komponentteja ja on siten 
potentiaalinen raaka-ainelähde uusille sovelluksille niin elintarvike-, lääke-, 
kosmetiikka- kuin bioteknologiaa hyödyntävälle teollisuudelle.  Yksi tällainen 
potentiaalinen komponentti on ovomusiiini. Ovomusiini on valkuaisen proteiini, 
joka ylläpitää sakean valkuaisen geelimäistä rakennetta.  
Tämän työn tavoitteena oli kehittää eristysmenetelmiä ovomusiinille, 
karakterisoida sen rakennetta ja verrata erilaisia valkuaisfraktioita ovomusiinin 
lähteenä. Tutkimuksessa verrattiin sekä entsymaattisten että erilaisten 
fysikaalisten menetelmien vaikutusta ovomusiinin liukoisuuteen. Lisäksi 
tutkittiin ovomusiinin ja siitä lohkottujen peptidien bioaktiivisia ominaisuuksia. 
Ovomusiinin eristämiseksi kehitettiin yksinkertainen ja nopea menetelmä, 
jonka avulla ovomusiini voidaan eristää kananmunasta muutamassa tunnissa, 
kun monilla muilla menetelmillä siihen kuluu 1-2 päivää. Rakenteellisesti 
ovomusiini näytti koostuvan vain kahdesta alayksiköstä, α- ja β-ovomusiinista, 
koska aikaisemmin α1-ovomusiiniksi nimetty proteiini on tutkimusten mukaan 
ovostatiini. Todennäköisesti ovostatiini on kuitenkin vuorovaikutuksessa 
ovomusiinin kanssa siten, että sillä on myös vaikutusta kananmunan 
valkuaisosien rakenteellisiin ominaisuuksiin. 
 Teollisen munatuotteen, valkuaismassan, valmistuksen yhteydessä 
muodostuva sivuvirtajae, ns. suodatusfraktio, sisälsi runsaasti ovomusiinia. 
Valmistusprosessien kehittyessä sivuvirtajakeen määrä on kuitenkin 
pienentynyt niin merkittävästi, ettei sen hyödyntäminen ovomusiinin lähteenä 
ole enää käytännöllistä. Käytännön kannalta teollinen valkuaismassa oli 
potentiaalisin vaihtoehto tutkituista valkuaisfraktioista. Tutkimuksessa 
verrattiin sekä entsymaattisten että fysikaalisten menetelmien vaikutusta 
ovomusiinin liukoisuuteen. Fysikaalisista menetelmistä sonikoinnin avulla 
ovomusiini liukeni parhaiten, mutta myös kolloidimylly on potentiaalinen 
vaihtoehto. Sen avulla saatiin aikaiseksi maitomainen, opaalinen ja 
rakenteeltaan miellyttävä ovomusiinisuspensio. Sekä fysikaalisilla että 
entsymaattisilla menetelmillä voitiin tuottaa ovomusiinipreparaatteja, jotka 
estivät Newcastlen tautia aiheuttavan viruksen kasvua. Entsymaattisen 
hydrolyysin avulla tuotettu ovomusiinipreparaatti esti myös lintuinfluenssaa 
aiheuttavan viruksen kasvua in vitro.     
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1 INTRODUCTION 
The hen’s egg is a one of the most multipurpose of foods. It is rich in high 
quality proteins and fats, valuable minerals and trace elements, together with 
vitamins. In addition, the bioavailability, i.e. the absorption, of these 
nutritionally important components, is excellent from eggs1.  Furthermore, eggs 
are one of a few so-called multifunctional foods. Thus, they are used widely in 
the food industry e.g. due to their foaming, gelling and emulsification 
properties.   
Structurally, eggs are composed of three parts: the eggshell (including 
eggshell membranes), the white (or albumen), and the yolk. On average, the 
yolk comprises 30%, the white 60% and the eggshell 10% of the weight of the 
egg. Egg white is further divided into four distinct layers: outer thin white, 
thick white, inner thin white and the chalaziferous layer or inner thick white. 
The shares of each layer are about 23%, 57%, 17% and 3%, respectively2. 
Proteins are present both in the egg white and the yolk, while virtually all the 
lipids are in the yolk. Minerals are the major component of the eggshell. More 
detailed chemical compositions for Finnish eggs are available on the Fineli 
database (http://www.fineli.fi/). The weight and composition of each part of 
hen’s egg is affected by various factors such as the age of the hen, hybrid and 
feeding3. 
As a hen is laying an egg, its aim is not to produce food for humans but to 
give a birth to a new life. Thus the biological roles of both eggshell and egg 
white are to protect the yolk (and embryo) from mechanical impacts and the 
penetration of pathogens. In addition, during hatching the egg white serves as a 
nutriment for the developing embryo4. The defence mechanism of the egg 
white is acting both physically and chemically. The gel-like consistency of egg 
white attenuates the effect of external shocks and serves as a barrier for 
microbial movement. Moreover, in fresh eggs both thick egg white layers and 
chalaza cords are working together to keep the yolk in the middle of the egg5. 
The chemical defence is based mainly on the action of egg white proteins.  
Many of the proteins have distinctive properties that suggest antimicrobial 
activity e.g. proteinase inhibition or ability to bind nutrients (vitamins, trace 
elements) that are essential for microbes6.The exact number of egg white 
proteins is not known, but by using mass spec techniques 158 proteins have 
been identified, and a further 44 proteins were identified tentatively7. Naturally, 
most of these proteins exist in small quantities, and a little over ten proteins 
comprise about 96% of total egg white proteins3,8. 
One interesting egg white protein is ovomucin, a sulphated glycoprotein, 
characterised by a high molecular weight and a subunit structure, first 
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2 
described by Eichholz9. In addition to egg white, ovomucin is also found in 
chalazae 10,11 and in the outer layer of the vitelline membrane12-15. Ovomucin is 
responsible for the gel-like properties of thick egg albumen. Fresh eggs having 
high quality egg white (expressed as Haugh units) have been reported to 
contain much more ovomucin in thick white than low quality eggs16,17. Egg 
white thinning, the most important change in egg white during storage, is 
usually attributed to the degradation of the ovomucin complex18,19. In addition, 
ovomucin and ovomucin-derived peptides have been found to involve different 
kinds of biological activities. In the review following, the physical and 
chemical characteristics, isolation methods and various properties of ovomucin 
will be discussed in more detail. 
.  
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2 REVIEW OF THE LITERATURE 
2.1 Chemical and structural characterization of ovomucin  
2.1.1 Ovomucin subunits 
It is generally recognized that ovomucin is comprised of at least two subunits: 
α-ovomucin and β-ovomucin20,21. In addition, Itoh et al.11 reported that the α-
ovomucin, which was fractioned by gel filtration chromatography (GFC), 
separated into two bands on SDS-PAGE. They named these compounds α1- 
and α2-ovomucin, and further estimated the molecular weights (MWs) 150, 
220 and 400 kDa for α1-, α2- and β-ovomucin, respectively, by using SDS-
PAGE. Similar SDS-PAGE patterns for reduced crude ovomucin have been 
reported by many authors22-28. Numerous studies have confirmed the presence 
of β-ovomucin in the gel region 350˗400 kDa, and indicated that the primary 
area for α-ovomucin seems to be 200˗250 kDa in SDS-PAGE7,11,23,24,28,29-31. 
However, the identity of 150 kDa protein is somewhat uncertain. 
Shan et al.26 have further identified the SDS-PAGE bands corresponding to 
α1- and α2-ovomucin by using tryptic peptide mass analysis, and reported that 
all the amino acid sequences of peptides obtained from these bands were 
similar to that of α-ovomucin32. In addition, Hayakawa & Sato33 reported that 
monomeric α-ovomucin tended to dimerize in dilute salt solutions. Robinson & 
Monsey21 have also noted that the reduced α-ovomucin showed multiple 
sedimentation coefficient values in the phosphate buffer. Similar heterogenous 
behaviour, e.g. the existence of three compounds, during sedimentation 
velocity measurements of ovomucin, has also been reported by several 
authors34-36.  
By contrast, Offengenden et al.30,31 have reported, that the primary protein 
detected in 150 kDa band by using mass spectra analysis was found to be 
ovostatin37,38. Similarly, although LC-MS/MS analysis revealed α-ovomucin 
existence on SDS-PAGE in gel region of 100˗250 kDa, and for ovostatin in a 
gel region of 80˗200 kDa, the primary area seems to be 200˗250 kDa for α-
ovomucin and about 150˗180 kDa for ovostatin7,29. Moreover, the molecular 
weight of ovostatin subunit has been estimated to be 162˗195 kDa38-41.   
Summarizing, it seems quite likely that, at least in fresh eggs, the main 
proteins in SDS-PAGE gel regions approximately 350˗400, 200˗280 and 
150˗180 kDa are β-ovomucin, α-ovomucin and ovostatin, respectively. 
However, the existence of smaller α-ovomucins migrating in lower gel regions 
cannot be totally excluded. As stated by Offengenden et al.30, degradation of α-
ovomucin could happen during egg storage or ovomucin isolation. Very likely 
the same applies to β-ovomucin.  
Review of the Literature 
 
 
4 
2.1.1.1 α-Ovomucin – a proteinaceous subunit 
The literature review of amino acid and carbohydrate compositions for α-
ovomucin obtained from various egg white fractions are shown in Table 1 and 
2, respectively.  As can be seen in Table 1 α-ovomucin seemed to be rich both 
in aspartic acid and glutamic acid, thus contributing to the negative charge of 
ovomucin and suggesting the existence of N-glycans. Moreover, α-ovomucin 
contains about twice the amount of cysteine as β-ovomucin, and these residues 
are supposed to enable both the dimerization of α-ovomucin and the 
polymerization of ovomucin molecules33.  
 
 
 
Fig. 1 Possible structures of α-ovomucin N-glycans. These branched chain 
oligosaccharides are linked to asparagine residues30,31.   
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The primary amino acid sequence of α-ovomucin was introduced by 
Watanabe et al.32 The polypeptide consists of 2,108 amino acids with a relative 
molecular mass of 233,553 Da.  Thus the estimated size of α-ovomucin could 
be calculated to be 256˗278 kDa, because carbohydrate content of α-ovomucin 
has been reported to vary from 9.2% to 15.5% (Table 2). Analytically, the MW 
of α-ovomucin has been estimated to be 210˗250 kDa or 180˗210 kDa by using 
SDS-PAGE11,17,23,27,30,31 or analytical ultracentrifugation 21,33, respectively.  
α-Ovomucin has been supposed to contain N-glycans as the main 
carbohydrates are mannose and N-glucosamine (Table 2), and it was also 
reported to contain 24 potential N-glycosylation sites32. Offengen et al.30,31 
have studied N-glycolysation of ovomucin in more detail. They found 18 
potential N-glycolysation sites in α-ovomucin, of which two were non-
glycolysated, and one site was occupied as both glycolysated and non-
glycolysated form. The remaining 15 sites were glycolysated. Interestingly, 
glycopeptide analysis of five glycosylation sites revealed glycan heterogeneity, 
even up to five glycans per site. The identified glycans were found to have a 
pentasaccharide core of GlcNAc2Man3 and a bisecting GlcNAc. These glycan 
forms are also typical of other EW proteins, such as ovalbumin, ovotranferrin 
and ovomucoid47, and as glycolysation is known to be tissue- and species-
specific48, it was assumed that N-glycans of α-ovomucin have equal structures 
as the above-mentioned egg white (EW) proteins. Figure 1 shows possible 
structures of α-ovomucin N-glycans as proposed by Offengenden et al30. In 
their studies no terminal sialic acids were reported, although α-ovomucin has 
been reported to contain a small amount of sialic acid (Table 2).  
2.1.1.2 β-Ovomucin – a carbohydrate-rich subunit 
The results of a corresponding literature review of amino acid and carbohydrate 
compositions for β-ovomucin obtained from various egg white fractions are 
shown in Table 3 and 4, respectively. The most abundant amino acids are 
serine and threonine (Table 3) thus suggesting the existence of O-glycosidic 
glycans. Figure 2 shows the structures of several O-glycans released from 
ovomucin by β-elimination. Most likely these glycans are from β-ovomucin, as 
it contains most of the galactose and sialic acid found in ovomucin. The 
carbohydrates are presented in ovomucin as oligosaccharide moieties 
consisting of about 2˗6 carbohydrate units having both straight and branched 
chains and also containing terminal sialic acid and ester sulphates. Moreover, 
two potential N-glycolysation sites have been identified in β-ovomucin30,31.   
To the author’s knowledge, the complete amino acid sequence of β-
ovomucin has not been revealed officially so far. Watanabe et al.56 reported 
already in the early 2000s an amino acid sequence of a β-ovomucin fragment 
consisting of 827 amino acids and having a molecular weight of 91,836 Da. 
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Since then, this sequence has been upadated several times, but the status of β-
ovomucin sequence is still partial, consisting of 1,185 AAs with a molecular 
mass of 132,217 Da. However, it should be noted that a website of GenScript 
(http://www.genscript.com/cgi-bin/orf/refseq.pl?acc=XM_426405) gives a 
predicted amino acid sequence for β-ovomucin. This sequence consists of 
2,677 amino acids, including the above-mentioned partial sequence. The 
relative molecular mass of β-ovomucin was estimated to be 291,308 Da by 
using the ProteinCalculator 3.4 program57. Furthermore, the estimated size of 
β-ovomucin could be calculated to be about 630 kDa, if it is assumed the 
carbohydrate content of β-ovomucin is on average about 54% (Table 4). 
Interestingly, this value is within a range obtained in previous analytical studies, 
as the molecular weight of the β-ovomucin subunit has been estimated by SDS-
PAGE or ultracentrifugation to be between 350 and 720 kDa7,11,17,23,24,27-
31,33,46,58. Although these results are quite promising, it should be noted that this 
GenScript-sequence has not been published or loaded into any protein sequence 
database, such as UniProt (http://www.uniprot.org/). Thus, it has not been peer-
reviewed. 
2.1.2 Ovomucin complex 
Egg white contains two forms of ovomucin: insoluble and soluble ovomucin. 
Soluble ovomucin is present both in thick and thin albumen, while insoluble 
ovomucin is found only in thick albumen59. In addition, thick white can be 
divided into gel and liquid fraction by using ultracentrifugation18. Insoluble and 
soluble ovomucin contain different proportions of ovomucin subunits (Table 5). 
Insoluble ovomucin seems to contain about 2.5 times the β-ovomucin 
compared to that in soluble ovomucin. This abundance is attributed to the 
higher apparent viscosity of insoluble ovomucin than that of soluble 
ovomucin63. Similarly, the molecular weight of insoluble ovomucin is greater 
than that of soluble ovomucin. The MW values from 27 to 56 × 106 Da for 
insoluble ovomucin in 1.1 M KCl (pH 7.9) were estimated using light 
scattering64. For soluble ovomucin, molecular weight values in the range from 
5.6 to 8.3 × 106 Da have been reported35,36,45,65. The variation of molecular 
weights in both ovomucin forms is presumably due to differences in both 
measuring methods and conditions and the heterogeneity of ovomucin 
 
 
 
 
 
 
  
T
ab
le
 3
 A
m
in
o 
ac
id
 c
om
po
si
tio
ns
 o
f β
-o
vo
m
uc
in
 su
bu
ni
ts
 o
bt
ai
ne
d 
fr
om
 v
ar
io
us
 e
gg
 w
hi
te
 fr
ac
tio
ns
. 
E
gg
 fr
ac
tio
n 
 
Am
in
o 
ac
id
 (m
ol
/1
00
 m
ol
) 
  
Al
a 
Ar
g 
As
p 
Cy
s 
G
lu
 
G
ly
 
H
is 
Ile
 
Le
u 
Ly
s 
M
et
 
Ph
e 
Pr
o 
Se
r 
Th
r 
Tr
p 
Ty
r 
Va
l 
Re
f. 
T
hi
ck
 e
gg
 w
hi
te
 
6.
4 
2.
6 
7.
2 
5.
4 
8.
6 
4.
6 
1.
7 
3.
9 
6.
9 
5.
1 
1.
4 
3.
0 
7.
4 
14
.3
 
13
.3
 
0.
8 
2.
5 
4.
9 
21
 
 
5.
0 
2.
6 
5.
9 
3.
0 
8.
2 
4.
3 
2.
1 
3.
9 
7.
0 
6.
1 
1.
6 
3.
8 
8.
7 
15
.9
 
14
.3
 
nd
 
2.
6 
5.
1 
11
 
 
7.
7 
1.
6 
4.
8 
1.
4 
7.
9 
3.
2 
1.
1 
4.
1 
7.
3 
4.
6 
4.
4 
2.
6 
9.
0 
18
.9
 
14
.8
 
nd
 
1.
7 
4.
9 
27
 
M
ea
n 
± 
SD
 
6.
4 
± 
1.
4 
2.
3 
 
± 
0.
6 
6.
0 
± 
1.
2 
3.
3 
± 
2.
0
8.
2 
± 
0.
4
4.
0 
± 
0.
7
1.
6 
± 
0.
5
4.
0 
± 
0.
1
7.
1 
± 
0.
2
5.
3 
± 
0.
8 
2.
5 
± 
1.
7
3.
1 
± 
0.
6
8.
4 
± 
0.
9
16
.4
 
± 
2.
3
14
.1
 
± 
0.
8
0.
8 
2.
3 
± 
0.
5
5.
0 
± 
0.
1 
 
T
hi
n 
eg
g 
w
hi
te
 
5.
4 
2.
8 
5.
8 
3.
1 
7.
7 
4.
7 
1.
8 
3.
5 
6.
6 
5.
3 
1.
7 
3.
6 
9.
5 
15
.7
 
15
.8
 
nd
 
2.
4 
4.
6 
11
 
G
el
 (T
hi
ck
) 
6.
2 
2.
4 
8.
7 
2.
3 
8.
1 
5.
3 
1.
3 
4.
2 
7.
3 
5.
8 
1.
8 
3.
5 
4.
9 
14
.5
 
14
.7
 
nd
 
2.
8 
5.
5 
42
,4
3 
 
6.
0 
1.
1 
2.
6 
2.
5 
5.
6 
2.
1 
1.
1 
7.
2 
7.
3 
3.
0 
1.
1 
2.
6 
8.
9 
18
.4
 
20
.0
 
nd
 
6.
1 
3.
1 
44
 
 
6.
1 
3.
8 
6.
4 
2.
5 
9.
6 
5.
6 
2.
6 
4.
0 
7.
2 
6.
1 
1.
8 
4.
3 
5.
5 
12
.8
 
12
.8
 
nd
 
2.
8 
6.
2 
45
 
M
ea
n 
± 
SD
 
6.
1 
± 
0.
1 
2.
4 
 
± 
1.
4 
5.
9 
± 
3.
1 
2.
4 
± 
0.
1
7.
8 
± 
2.
0
4.
3 
± 
1.
9
1.
7 
± 
0.
8
5.
1 
± 
1.
8
7.
3 
± 
0.
1
5.
0 
± 
1.
7 
1.
6 
± 
0.
4
3.
5 
± 
0.
9
6.
4 
± 
2.
2
15
.2
 
± 
2.
9
15
.8
 
± 
3.
7
nd
 
3.
9 
± 
1.
9
4.
9 
± 
1.
6 
 
Li
qu
id
 (T
hi
ck
) 
5.
2 
2.
4 
4.
8 
3.
4 
6.
5 
3.
7 
1.
9 
8.
6 
7.
4 
5.
7 
1.
1 
2.
5 
7.
2 
15
.2
 
13
.5
 
2.
0 
5.
1 
4.
2 
44
,4
6 
nd
 =
 n
ot
 d
et
er
m
in
ed
, S
D
 =
 st
an
da
rd
 d
ev
ia
tio
n 
 
Review of the Literature 9
  
T
ab
le
 4
 C
ar
bo
hy
dr
at
e 
co
m
po
si
tio
ns
 o
f β
-o
vo
m
uc
in
 su
bu
ni
ts
 o
bt
ai
ne
d 
fr
om
 v
ar
io
us
 e
gg
 w
hi
te
 fr
ac
tio
ns
.  
   
   
 
E
gg
 fr
ac
tio
n 
 
Ca
rb
oh
yd
ra
te
s (
%
 o
f o
vo
m
uc
in
) 
 
H
ex
os
es
 
M
an
 
G
al
 
H
ex
os
am
in
es
 
G
lc
N
Ac
 
G
al
N
Ac
 
N
AN
A 
To
ta
l 
Re
f. 
T
hi
ck
 e
gg
 w
hi
te
 
23
.3
 
4.
1 
19
.2
 
19
.7
 
11
.0
 
8.
7 
13
.8
 
56
.8
 
21
 
 
19
.6
 
0.
2 
19
.4
 
13
.7
 
7.
6 
6.
1 
14
.9
 
48
.2
 
11
 
 
29
.9
 
0.
6 
29
.3
 
18
.6
 
11
.4
 
7.
2 
18
.2
 
66
.7
 
27
 
M
ea
n 
± 
SD
 
24
.3
 
± 
5.
2 
1.
6 
 
± 
2.
1
22
.6
 
± 
5.
8 
17
.3
 
± 
3.
2 
10
.0
 
± 
2.
1 
7.
3 
± 
1.
3 
15
.6
 
± 
2.
3 
57
.2
 
± 
9.
3 
 
T
hi
n 
eg
g 
w
hi
te
 
18
.0
 
0.
2 
17
.8
 
15
.2
 
7.
1 
8.
1 
19
.1
 
52
.3
 
11
 
G
el
 (T
hi
ck
) 
18
.4
 
1.
5 
16
.6
 
18
.3
 
10
.4
 
7.
9 
11
.4
 
48
.1
 
42
,4
3 
 
20
.1
 
0.
4 
19
.7
 
21
.6
 
11
.8
 
9.
8 
15
.3
 
57
.0
 
44
 
 
18
.4
 
0.
4 
18
.0
 
19
.9
 
11
.3
 
8.
2 
12
.3
 
50
.6
 
45
 
M
ea
n 
± 
SD
 
19
.0
 
± 
1.
0 
0.
8 
 
± 
0.
6
18
.1
 
± 
1.
6 
19
.9
 
± 
1.
7 
11
.2
 
± 
0.
7 
8.
6 
± 
1.
1 
13
.0
 
± 
2.
0 
51
.9
 
± 
4.
6 
 
Li
qu
id
(T
hi
ck
) 
19
.8
 
0.
4 
19
.4
 
19
.1
 
11
.1
 
8.
0 
12
.6
 
51
.5
 
44
,4
6 
nd
 =
 n
ot
 d
et
er
m
in
ed
, S
D
 =
 st
an
da
rd
 d
ev
ia
tio
n 
Review of the Literature 10 
  
   
   
 
Fi
g.
 2
 S
tru
ct
ur
es
 o
f O
-g
ly
ca
ns
 o
f o
vo
m
uc
in
. O
lig
os
ac
ch
ar
id
e 
m
oi
et
ie
s c
on
si
st
 o
f 2
-6
 c
ar
bo
hy
dr
at
e 
un
its
 w
ith
 b
ot
h 
st
ra
ig
ht
 a
nd
 b
ra
nc
he
d 
ch
ai
ns
 th
at
 a
re
 li
nk
ed
 to
 se
rin
e 
an
d 
th
re
on
in
e 
re
si
du
es
49
-5
5 . 
 
Review of the Literature 11
Review of the Literature 
 
 
12 
Table 5 Percentage distribution of ovomucin subunits in various ovomucins. 
Egg layer/ovomucin form Percentage distribution (%) Ref. 
β-ovomucin α-ovomucin 
Thick /insoluble 27 73 60 
 
Thin/soluble 
34 
12 
66 
88 
61 
60 
Chalazae/insoluble 21 79 62 
    
Gel/insoluble 33 67 46 
Liquid/soluble 13 87 46 
 
The literature review of amino acid and carbohydrate compositions of 
ovomucin complex obtained from various egg white fractions is presented in 
Table 6 and 7, respectively. Surprisingly, the variation of AA compositions 
among various egg white layers seemed to be quite moderate. Actually, the 
variation within groups seemed to be about the same magnitude as between the 
groups. In contrast, the carbohydrate composition of various ovomucins varied 
considerably: ovomucins obtained from whole, thick and thin egg white 
contained carbohydrates about 18%, 31% and 19% of ovomucin, respectively 
(Table 7). In addition, the carbohydrate content for gel and liquid fractions was 
33% and 16%, respectively. These differences are related to the variation of β-
ovomucin content in ovomucin complexes (Table 5).   
2.2  Isolation and purification of ovomucin 
2.2.1  Isoelectric precipitation method 
Ovomucin is usually fractionated from egg albumen by using the isoelectric 
precipitation (IEP) method. Numerous variations of this method are presented 
in the literature, but usually the IEP method can be said to comprise three steps 
as follows: precipitation, collection and the washing step. However, in some 
methods an additional step is added before ovomucin precipitation as lysozyme 
has been removed by crystallization from egg white66,77-79. However, the 
effectiveness of this procedure seemed to be somewhat questionable, since 
SDS-PAGE showed that the obtained ovomucin preparations still contained 
lysozyme as an impurity81.    
In the precipitation step egg albumen is usually diluted with water, followed 
by acidification to or near to its isoelectric point. Quite often, the pH is adjusted 
to pH 6.018,22,23,60,80,81, but both lower (4.5˗5.0)66,77-80 and higher (7˗8)80,82 pH-
values have also been used. Different acids, such as H2S0418,20,60, HCl23,79, 
acetic acid78,80,82 or lactic acid22, could be used for acidification. Alternatively, 
egg white might be diluted with water11,17,19,21,58,61,83,84 or salt solution18,76,85 
without any pH control.  
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In general, the collection step is carried out by using centrifugation. 
Ovomucin precipitation has also been collected by settling64,67,86 or by sieve23,87. 
In the washing step ovomucin precipitate is washed several times with salt 
solutions, such as 2% KCl, to remove other egg white proteins, and finally with 
water to wash out salts. Alternatively, salts may be removed by using a dialysis 
step,88,89. 
Ovomucin has been reported to interact with lysozyme20,35,43,90-93 as well as 
with other egg white proteins, lsuch as ovalbumin and ovotransferrin in vitro94. 
In addition to ovomucin, lysozyme has also been reported to form complexes 
with other egg white proteins, such as ovalbumin, ovotransferrin, ovoglobulins 
and ovomucoid94,95. Thus it is not surprising, that in addition to ovomucin, the 
crude ovomucin precipitate also contains ovotransferrin, ovalbumin, 
ovomucoid and lysozyme (Figure 3). Crude ovomucin without salt washings 
has been reported to have a purity of about 64%24-26. Conventionally co-
precipitated proteins were removed with repeated salt washings, although 
previous studies have shown that extensive KCl washing cause a loss of 
ovomucin80,97. According to Lyndrup80, only 120 mg of ovomucin was obtained 
from 100 ml of thick egg white after an extensive washing procedure, while the 
KCl washings contained altogether about 360 mg of ovomucin. Also, Omana & 
Wu25 reported similar results as they extracted ovomucin with 500 mM KCl: 
the ovomucin yield was about 105 mg compared to 260 mg obtained without 
salt washings.  
 
 
 
Fig. 3 Elution profile of crude ovomucin obtained by Superose 6 HR gel-
filtration chromatography96. 1 = -ovomucin, 2 = -ovomucin, 3 = ovostatin, 4 
= ovotransferrin, 5 = unknown (globulins?), 6 = ovalbumin, 7 = ovomucoid and 
8 = lysozyme. Reprinted from Hiidenhovi 2007 with permission. Copyright 
2007 Springer Science+Business Media. 
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Recently, modifications of the IEP method have been proposed, which 
seemed to overcome this reduction in ovomucin yield24-26,28. In this so-called 2-
step method, ovomucin was isolated by using two consecutive salt precipitation 
steps. It has been reported that, by using the 2-step method, it was possible to 
obtain a high yield (over 400 mg/100g of EW) of ovomucin. However, a closer 
examination of GFC elution profiles of the ovomucin obtained by 2-step 
methods indicated that the crude ovomucin precipitate seemed to contain quite 
a lot of salt as an impurity24,25,28. Actually, when the 2-step method was 
modified by adding a dialysis step, the yield obtained was reduced by half, but 
the purity was still high, about 90%88,89. Shan et al.98 modified the ovomucin 
purification method even further; the ovomucin precipitate obtained by the 2-
step method was further washed several times with mild (10 mM) NaCl 
solution followed by a dialysis step. The final purity of ovomucin was 
calculated to be 96.7%, but no yield was reported.  
However, regardless of which method is used, the crude ovomucin 
precipitate obtained has a limited solubility into conventional aqueous buffer 
solutions, and can be solubilised completely as subunits with buffers containing 
dissociating agents such as urea, guanidine hydrochloride or SDS, and reducing 
agents such as β-mercaptoethanol or dithiotreitol12,22,34. In addition, there are 
several studies in which sonication were used to solubilize ovomucin11, 33,46,46,99-
103. Alternatively, crude ovomucin can be solubilized by enzymatic hydrolysis 
to peptides23,52,81,87,99,100,104-107. The advantage of the IEP method is that the 
method itself is very simple, cost-effective and easy to up-scale. Figure 4 
shows ovomucin isolation by using the IEP method on a laboratory scale. 
 
 
 
Fig. 4 Schematic diagram of ovomucin isolation by the IEP method. 
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2.2.2  Chromatographic methods  
Alternatively to precipitation methods, whole ovomucin has been isolated from 
egg albumen by using gel filtration chromatography. The molecular weight of 
ovomucin is so substantial compared with other egg white proteins that by 
choosing appropriate gel filtration media, ovomucin will be eluated much 
before the other egg albumen proteins (Figure 5). Ovomucin has been isolated 
from egg albumen in a complex form using GFC both without and with 
detergents as presented in Table 8. As can be seen in Table 8, much higher 
flow rates could be used with Sephacryl S-500 due to its rigid structure 
compared to Sepharose 4B gel. Naturally, a higher flow rate facilitated a timely 
shorter separation process. Due to this tolerance of high flow rates and high 
chemical stability, Sephacryl S-500 is well suited for industrial applications110.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 Elution profile of whole egg white obtained by Sephacryl S-500 HR gel-
filtration chromatography96. Arrow pointing to ovomucin. Reprinted from 
Hiidenhovi 2007 with permission. Copyright 2007 Springer Science+Business 
Media. 
One advantage of the GFC method compared with IEP is that the separated 
ovomucin is usually very pure (free from other egg white proteins) and already 
in soluble form. The main disadvantage of GFC is a low yield of ovomucin; the 
reported values are quite modest: 5˗10 mg per GFC run34,69. Although this is 
also an upscaling issue, the main reason for the low yield is that samples for 
GFC are prepared by diluting egg white with a buffer, thus leading to samples 
containing low amounts of ovomucin. An alternative method to increase the 
ovomucin yield obtained by GFC has been presented by Hiidenhovi et al.109   
This study is discussed in more detail in Chapter 5.1.2.   
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In contrast to IEP methods, chromatographic methods also enabled the 
isolation of ovomucin subunits. Most often ovomucin is separated into α- and 
β-subunits by using GFC in reducing conditions. Table 9 shows several 
examples of GFC applications both for preparative and for analytical scale. 
Also other chromatographic methods, such as lysozyme-Sepharose 4B affinity 
chromatography45 and ion-exchange chromatography after sonication44,112,113 
have been used for subunit isolation. 
In addition, GFC methods have been used for both purification and purity 
analysis of reduced ovomucin in a way that subunits were eluated as a single 
peak at column void. Examples of such methods are shown in Table 10.  
2.2.3 Other methods 
Garipaldi et al.82 separated ovomucin from EW by using preparative 
ultracentrifuge (59,000 × g at 4°C for 16 hrs). The purity of the precipitate 
obtained was low, about 30%, but nevertheless it contained about 96% of 
ovomucin that was obtained by using the IEP method. In addition ovomucin 
was isolated by high-speed centrifugation at high ionic strength71. Ovomucin 
has been separated into α- and β-ovomucin using density gradient 
ultracentrifugation21 and density gradient electrophoresis42.  
2.3 Properties of ovomucin 
2.3.1 Biological role  
Ovomucin is generally recognized as being responsible for the gel-like 
properties of thick egg albumen, as the most notable difference between thick 
and thin egg white is the amount of ovomucin. Analytical studies indicated that 
thick white contained either about two times (1.4˗2.3)19,23,34,59,60,114,115 or at least 
four times (3.8˗6.0)17,83,117-119 more ovomucin than thin egg white. This 
variation can be attributed to hen hybrid and/or age, freshness of the eggs as 
well as different isolation and analysis methods.  
Several studies have suggested that the mechanical properties of thick white 
cannot be explained as a network formed by ovomucin alone, but a better 
explanation is that the network is formed by the ovomucin-lysozyme 
complex83,102,120. However, the ovomucin preparations used in those studies 
contained more or less lysozyme as an impurity and this might have effected to 
these results. Although the occurrence of ovomucin-lysozyme interaction in 
egg white cannot be ruled out, it might be irrelevant for the gel-forming 
properties of ovomucin, as it has been noted that ovomucin is able to form a gel 
individually 31,63,121. Hayakawa & Sato63 noted that the apparent viscosity of 
Review of the Literature 
 
 
22 
soluble ovomucin increased rapidly above 1.5 mg/ml, and at the concentration 
of 2.0˗2.5 mg/ml it formed a gel, whose viscosity was comparable to that of 1.5 
mg/ml insoluble ovomucin. Offengenden & Wu121 showed that at various 
concentrations (0.5%, 1% and 2%) ovomucin spontaneously formed a gel upon 
hydration at room temperature. The rheological properties of these gels were 
similar to structured fluids and other mucins. Similar non-Newtonian behaviour 
of ovomucin gels has also been reported by Rabouille et al.101,102.   
Actually egg white very much resembles mucus, a complex secretion, which 
covers the mucosal surfaces of the body, such as gastrointestinal and 
respiratory tracts, which are exposed to the external environment. Mucus is 
composed mainly of water (~96%) containing also salts, lipids and proteins, 
which have a defensive purpose such as lysozyme. The main compound is 
mucin, a large glycoprotein that is responsible for the viscous and gel-like 
properties of mucus122-125. Without lipids, this description equates extremely 
well to egg white.  
This resemblance is quite expected as ovomucin belongs genetically into 
mucins. It has been found that ovomucin is encoded by two genes located on a 
locus on chromosome 5 in chicken. That locus is encoding gel-forming mucins 
(Muc6, Muc2, Muc5ac and Muc5b) and is quite similar to the corresponding 
human locus. The most significant difference is the presence of an additional 
gene in the chicken genome between Muc2 and Muc5a, an ovomucin gene, 
which encodes α-ovomucin subunit. In addition it has been noted that β-
ovomucin is the orthologue of human MUC6126,127.  
Also, the biological role of ovomucin is same as that of mucus and egg 
white; protection. The gel-like structure of thick egg white induced by 
ovomucin hinders the movement of micro-organisms through to the albumen 
and also protects the developing embryo from impacts. In addition, ovomucin 
is known to contain antimicrobial activity against viruses and bacteria128-130.  
2.3.2 Role in egg white thinning 
During storage, the pH of egg white rises from pH 7.6 to pH 9.7 due to loss of 
carbon dioxide131,132. Simultaneously, the structure of thick egg white collapses 
and changes into liquid form. This phenomenon is called egg white thinning or 
liquefaction, and is the most important change in egg white during storage. It 
has been found that one reason for egg white thinning is intrinsic in the white 
itself, as sterile, separated egg whites thinned during storage133,134. Many 
theories have been suggested to explain egg white thinning, but there seems to 
be no general consensus among researchers about the causal factors which 
induce this phenomenon. Such theories have been reviewed, for example, by 
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Burley & Vadehra2, Li-Chan & Nakai8, Vadehra & Nath135 and Omana & 
Wu136. In what follows, another short review is presented.  
2.3.2.1 Enzyme action 
In one of the first theories presented for EW thinning it was suggested that 
ovomucin was degraded by a trypsin-like enzyme137. However, this was later 
refuted by Balls & Hoover117 who did not find any evidence of active or 
activatable proteinase in EW. Similar results were also reported by Lineweaver 
et al.138,139. In addition it has been found that the free amino acid content of 
whole egg remained constant during storage. This was reported to confirm that 
negligible, if any, proteolytic activity existed in eggs. The slow rise of free 
amino acids in EW was explained as being caused by the diffusion of amino 
acids from yolk to EW through vitelline membrane140.      
As the EW contains glycosidase activity, such as α-mannosidase and β-N-
acetylglucosaminidase activity141,142, it has been speculated that the enzymatic  
degradation some of the glycosidic bonds may cause egg white thinning91,143. 
However, the activities of both enzymes, especially α-mannosidase, are low in 
EW. In addition, it has been noted that, due to the pH-increase, the β-N-
acetylglucosaminidase activity gradually decreases in EW144-146. Moreover, it 
has been reported that the liquefaction of thick egg white did not lead to the 
release of free hexose or hexosamines119. Thus, it is very unlikely that any 
enzymatic degradation is involved in natural egg white thinning.   
2.3.2.2 Reactions of disulphide bonds of ovomucin 
Reduction of the disulphide bonds of ovomucin has been proposed to cause 
EW thinning, as it was found that minor amounts (less than 50 ppm) of 
reducing agents, such as thioglycol, hydrogen sulphide and sulphur dioxide, 
caused deteoration of egg white77,147. In addition, the alkaline degradation of 
disulphide bonds by hydroxide ion in alkaline pH was suggested to cause egg 
white thinning86. However, these latter experiments were carried out above pH 
11, while natural thinning occurs at lower pH. Therefore, the authors noted that 
different mechanism might be involved in egg white thinning86. Furthermore, a 
light scattering study64 of ovomucin demonstrated that alkaline degradation was 
very slow at pH 7.9. Therefore, it was postulated that a major part of the 
thinning was caused by disaggregation of gel-like aggregates.  
According to Beveridge & Nakai148, sulfhydryl blocking retained the 
thinning process, while Sato et al.85 reported that blocking has no effect on egg 
white thinning. Similarly, there are inconsistent results when change of 
sulfhydryl groups in stored eggs has been measured. Heath149 observed that the 
concentration of sulfhydryl groups in stored EW increased, in contrast to Kato 
et al.150 who noted no change during a 30-day storage. However, Kato et al.76 
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reported that the elution profile of ovomucin obtained by Sepharose 4B for 
thinned EW after a 20-day storage was similar to that of fresh thick white, in 
contrast to that of fresh thick white treated with reducing agent. In addition, 
they found that a definite amount of α-ovomucin remained insoluble even after 
a 60-day storage, but was readily solubilized by β-mercaptoethanol. Moreover, 
Miller et al.36 reported that apparent molecular weight (5.64 × 106 Da), amino 
acid and carbohydrate composition of native ovomucin were similar to those of 
ovomucin obtained from stored egg white, while the apparent MWs of reduced 
ovomucin were 309,500 and 726,200 Da. Thus, these results indicate that non-
covalent disaggregation of ovomucin takes place during egg white thinning, 
without disulphide degradation. 
2.3.2.3 Ovomucin-lysozyme interaction 
In addition to ovomucin, also lysozyme has been thought to participate in the 
formation of a gel structure of thick egg white20,83,86,91,102,151 and the change of 
ovomucin-lysozyme complex structure was thought to be a cause of egg white 
thinning. According to Hawthorne84, the reason for thinning was the 
breakdown of swollen ovomucin gel due to the formation of insoluble 
ovomucin-lysozyme complex. However, this was contradicted by Cotterill & 
Winter152 who studied ovomucin-lysozyme interaction in vitro. They noted that 
the interaction was highest at pH 7 and decreased as pH increased, suggesting 
that it is more likely that the dissociation of ovomucin-lysozyme complex 
might cause thinning. Later, Miller et al.36 studied ovomucin-lysozyme 
interaction by using sedimentation equilibrium ultracentrifugation. They noted 
that the interaction of lysozyme with native ovomucin at pH 6.9 was quite low: 
27% and 6% at ionic strength 0.07 and 0.13, respectively. As these 
experimental conditions were close to natural egg white, Miller et al.36 
suggested that ovomucin-lysozyme interaction is unlikely to be the principal 
reason for egg white thinning.  
2.3.2.4  Changes in the ovomucin subunit structure 
Thus, although the ovomucin-lysozyme interaction very likely exists in natural 
egg white, the changes in the ovomucin itself might be the reason for thinning. 
As mentioned above (Chapter 2.2) ovomucin consists of two subunits, namely 
β- and α-ovomucin, and it has been found that during egg white thinning β-
ovomucin is gradually dissociated and solubilized from a gel fraction of egg 
white to a liquid fraction, while a definite amount of α-ovomucin remained in 
gel fraction even after a 60-day storage18-21,43,61,76. Moreover, Kato et al.75 
reported that the release of β-ovomucin was delayed as eggs were kept in CO2-
storage, which has been shown131 to prevent egg white thinning. Sato et al.85 
suggested that an increase of pH during storage, reduced the ionic strength 
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induced by other EW proteins and rise of storage temperature seemed to be the 
main factors that favoured the specific release of β-ovomucin. Later, Kato et al. 
150 suggested that the release of O-glycosidically bound carbohydrate units of 
β-ovomucin due to β-elimination reaction in alkaline conditions might be the 
reason for the structural deteoration of ovomucin.  
Hayakawa et al.151 examined the effect of β-ovomucin on the solubility of α-
ovomucin with or without lysozyme. They noted that α-ovomucin formed an 
insoluble complex with lysozyme below pH 10, and β-ovomucin inhibited that 
complex formation in the neutral or slightly alkaline pH region. Relating to 
these and some other findings of their study, Hayakawa et al.151 suggested that 
the gel structure of thick EW ovomucin complex consists of α-ovomucin-
lysozyme complex covered by β-ovomucin. Furthermore, they suggested that 
the disaggregation of β-ovomucin due to alkaline reaction during storage leads 
to insolubization of the α-ovomucin-lysozyme complex, thus collapsing the gel 
structure of thick EW. 
2.3.2.5  Ovomucin and divalent cations 
The involvement of various divalent cations, such as calcium (Ca ) and 2+
magnesium (Mg2+), to EW thinning has also been investigated in several 
studies. The thinning of thick EW fraction of acidotic hens (feeds containing 
e.g. 3% NH4Cl) has been reported to be slower compared to normal eggs. This 
inhibition was suggested to be related to the maintenance of both pH and 
divalent cation (Ca2+ and Mg2+) content in eggs obtained from acidotic 
hens153,154. In addition, Sauveur155 has noted that after 20-days storage calcium 
and magnesium content in EW decreased by 63% and 21%, respectively, in 
control eggs compared to CO2-stored eggs. According to Monsey & 
Robinson156, thick EW of mature hens (age of 40˗65 weeks) contained less 
magnesium and also thinned more rapidly when compared to the thick EW of 
young hens. Moreover, Robinson & Monsey61 reported that addition of small 
amounts of NaCl or various magnesium salts to thick EW in vitro inhibited egg 
white thinning.  
The exact mechanism for how divalent cations affects egg white thinning or 
ovomucin gelling properties is not known. Although in vitro, it has been shown 
that both Mg2+ and Ca2+ inhibited the formation of ovomucin-lysozyme 
complex91, and that this interaction seemed to have minor importance to gel-
like properties of ovomucin, as discussed above. However, it has been reported 
that calcium has the ability to crosslink human gel-forming mucins into larger 
aggregates157,158. In addition, human mucin aggregates have been found to 
dissolve by pH increase and by removing calcium158. Interestingly, although the 
apparent viscosity of soluble ovomucin was increased slightly by the addition 
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of β-ovomucin, in the presence of a small amount of CaCl2 the observed 
increase was significant63.   
2.3.3 Techno-functional properties 
Egg white proteins contain multiple techno-functional properties such as 
gelling, foaming and emulsification. Therefore, eggs are largely used in the 
food industry. For example, egg white is one of the most widely used foaming 
agent for various food applications. Most often, foaming properties are 
evaluated by measuring the foaming capacity and stability. In addition, thermal 
coagulation of egg white foams is needed in many food products, especially in 
bakery products8,159. In what follows, the techno-functional properties of 
ovomucin are briefly reviewed. However, it should be noted that in most of 
these studies a soluble ovomucin or ovomucin treated in someway (e.g. 
sonicated or hydrolysed) is used to enhance its solubility. Thus, there is a 
certain lack of knowledge of the impact of untreated insoluble ovomucin on the 
techno-functional properties of ovomucin..     
Ovomucin has been reported to stabilize egg white foam160-162. According to 
Garipaldi et al.82 ovomucin-lysozyme complex was heat-denatured during egg 
white pasteurization causing a longer whipping time due to decrease of 
mechanical stability of the foam. Johnson & Zabik163-165 studied the effects of 
several egg white proteins singly and in combinations on the angel food cake 
system. They noted that as a single protein ovomucin, ovomucoid and 
lysozyme had little or no foaming capacity. However, ovomucin association 
with globulins enhanced foam formation but reduced cake volume. On the 
contrary, ovomucin-lysozyme interaction depressed foaminess, but produced 
large cakes. It was suggested that the role of ovomucin is to increase the 
viscosity of egg white and in this way participates in foam formation. 
Correspondingly, ovomucin-lysozyme complex was attributed to decrease 
viscosity, thus reducing foaming capacity.  
Kato et al.164 studied the relationship between the structural and functional 
properties of various ovomucin types such as soluble, sonicated and reduced 
ovomucin. In addition to its foaming properties, ovomucin was reported to 
have excellent emulsifying properties. Both the foaming power and foam 
stability of each ovomucin type studied were higher compared to that of bovine 
serum albumin (BSA). At higher protein concentrations (0.5%), the 
emulsifying activity of sonicated and reduced ovomucins was comparable to 
that of BSA. Moreover, the emulsion stability of sonicated and reduced 
ovomucins was much higher compared to that of BSA. The authors suggested 
that the foaming and emulsifying properties of ovomucins were dependent on 
viscosity and surface hydrophobicity, respectively164.     
Review of the Literature 
 
 
27
Later, Kato et al.165 examined the role of negatively charged sialic acid for 
the functional properties of ovomucin. They found that, even though the 
removal of terminal sialic acids reduced the viscosity of soluble ovomucin, its 
foaming properties were increased. According to Kato et al.165 the explanation 
for this contradictory phenomenon was the decrease of negative charge which 
enhanced the interaction of ovomucin molecules at the air-water interface, thus 
strengthening the foam film. In the case of both sonicated and reduced 
ovomucins foaming properties were increased after sialic acid removal without 
viscosity decrease. On the other hand, the emulsifying properties of various 
ovomucin types were markedly decreased due to sialic acid removal.  
More recently, Hammershøj et al.23 studied the foaming properties of the 
hydrolyzed ovomucin fractions. The foaming capacity of ovomucin increased 
along with the degree of hydrolysis (DH), and maximum foam overrun was 
reached at a DH range of 15 to 40%. Hydrolysis had no significant effect on the 
foam stability. Hammershøj et al.23 concluded that limited hydrolysis made it 
possible to increase the solubility and surface hydrophobicity of ovomucin, 
which might result in higher foaming capacity and possibly also enhanced 
foam stability.  
Shan et al.98 suggested that simple pH treatment was an effective way to 
enhance the functional properties of ovomucin. They reported that the alkali 
treatment had the greatest effect on for emulsifying properties, while weak acid 
treatment improved foaming stability.   
2.3.4 Bioactive properties  
In previous years, ovomucin was studied mainly because of its role in egg 
white thinning. More recently, however, there has been a growing interest 
within the food industry in health-promoting, functional foods. Today, proteins 
are not valuated only by the nutritional value or functional properties, but also 
by their biological activity. Most of the ovomucin research has lately been 
focused on its bioactive properties. 
2.3.4.1 Antiviral properties 
The antihemagglunation (AH) activity of ovomucin against the swine influenza 
virus was reported already in the late 1940s65,168,169. MacDonnell et al.170 
reported that this activity was remarkably resistant, as 0.5˗1% solution of 
ovomucin showed no activity loss e.g. in the following conditions: at pH 7.6 
100°C for 30 min, at pH 2 70°C for 60 min and at pH 11 70°C for 60 min. In 
addition, neither reduction nor chymotrypsin hydrolysis reduced the AH 
activity of ovomucin. However, both chemical fractionation and lyophilization 
significantly reduced activity170.     
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Tsuge et al.171 reported that ovomucin also has a hemagglunation inhibition 
(HI) activity against bovine rotavirus (RV), hen Newcastle disease virus (NDV) 
and human influenza virus (IV). Ovomucin was found to have the highest HI 
activity against all three viruses tested, compared to the other main EW 
proteins. In another study, Tsuge et al.172 noted that that not only the sialo-
oligosaccharide moieties were crucial for antiviral properties of ovomucin. 
Although the HI activity against NDV needed β-ovomucin (carbohydrate-rich 
subunit) only, that against RV was implemented its highest by macromolecular 
ovomucin including both ovomucin subunits. In contrast to earlier findings, 
both reduction and enzymatic hydrolysis seemed to reduce the HI activity of 
ovomucin, especially against RV, while against NDV this reduction was not so 
substantial.  
In further studies, the binding activities of various ovomucin fractions to 
NDV were evaluated by ELISA78,173,174. Pronase hydrolysis, heat treatment and 
pH increase were found to reduce the binding activity of ovomucin to NDV 
78,172,173. These studies also indicated that the terminal sialic acids of β- 
ovomucin contribute to the binding of ovomucin to NDV, as the binding of 
desialylated ovomucin to NDV was negligible173. In addition, it was 
demonstrated that the bound-type sialic acid was required for effective 
hemagglutination inhibition; the amount of free-type needed for 50% inhibition 
was 1,000 times that of bound-type173. Furthermore, a method of preparing 
Pronase-treated soluble ovomucin fragments having various binding activities 
to NDV was presented174.  
Recently, Shan et al.26,175 have reported that the addition of Mg2+ enhance HI 
and virus adhesion activities of ovomucin against NDV. They suggested that 
minimal amounts of Mg2+ (9 µmol/mg of ovomucin) coordinate with the 
carbohydrate moieties of ovomucin, thus making these functional groups more 
susceptible to cell signal recognition. 
2.3.4.2 Antitumour activity 
In preliminary studies, Ohami et al.176 noted that, by using scanning electron 
microscopy, the β-ovomucin subunit of ovomucin had a cytotoxic effect on 
cultured tumour cells (human melanoma cells). In further in vitro studies, 
sarcoma-180 (SR-180) cells were incubated with both α- and β-ovomucin 
obtained from gel fraction of EW112. It was noted that β-subunit supposedly 
inhibited the cell proliferation rate, in contrast to α-subunit, which 
predominantly had no effect to it. This cytotoxic effect of β-subunit was found 
to be both dose- and time-dependent. In addition, scanning and transmission 
electronmicroscopy demonstrated that β-ovomucin did not damage normal cells 
(mouse peritoneum macrophage cells), while SR-180 cells were clearly 
damaged. Moreover, it was shown that β-ovomucin did not induce apoptotic 
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DNA fragmentation. In the in vivo study that follows, the antitumour effect of 
β-subunit was tested against subcutaneously xenografted SR-180 cells in 
mice113. It was found that the intraperioneal administration of β-ovomucin first 
suppressed the growth of SR-180 cells and finally cured the tumour. Yokota et 
al.113 suggested that the antitumour properties of β-subunit was attributed to 
activating the immune system, as a vast accumulation of neutrophils, 
macrophages and lymphocytes were found in the side of the degraded and 
necrotic tumor tissue area. 
It was further demonstrated by using double grafted tumour system that 
certain highly glycosylated fragments separated from Pronase-treated 
ovomucin have antitumour properties177,178. Double grafted tumours were 
achieved for the BALB/c mice by simultaneous inoculations of Meth-A 
fibrosarcoma cells both in the right and left flank. Ovomucin fragments studied 
were 220 and 120 kDa, a highly glycosylated peptides derived from the β-
subunit177, and 70 kDa, a highly glycosylated peptide derived from α-
ovomucin178. As the β-subunit derived fragments were injected separately into 
the right tumour, it was found that both 220 and 120 kDa fragment cured 
directly and completely the treated tumour and inhibited indirectly and slightly 
the growth of distant (left) one. In the case of the 70 kDa fragment the direct 
antitumoural effect was not as potent, as the inhibition of the treated (right) 
tumour was described as “almost complete”, while the indirect effect was 
moderate. Moreover, treatment with desialylated 120 kDa fragment 
demonstrated that NANA moieties were not essential for direct antitumour 
effect, while it seemed to be obligatory for indirect antitumour activity. Further 
studies indicate, that presumably the 120 kDa fragment inhibit the growth of 
SR-180 cells due to interaction with SR-180 cells via basic fibroblast growth 
factor receptor179. 
2.3.4.3 Antiadhesive and antibacterial activity 
Ovomucin has been shown to inhibit colonisation of Helicobacter pylori, a 
bacterium which is associated with, for example peptic ulcers and gastric 
cancer180. Furthermore, ovomucin could eliminate H. pylori from the stomach 
in a concentration-dependent manner.  
It has been noted that ovomucin glycopeptide (OGP) obtained after Pronase 
digestion bound exclusively to E. coli O157:H7, and sialic acids were 
necessary for binding181,182. As the adhesion of bacteria to host tissues is a 
preliminary step in the foodborne illness, it was suggested that the OGP has the 
potential to provide protection against E. coli O157:H7 infection. Moreover, in 
the food hygiene field OGP might serve as a novel probe for E. coli O157:H7 
detection.  
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Recently, Shan et al.183 reported that ovomucin had antibacterial activity 
against E. coli and Salmonella measured by turbidimetry, and the minimal 
inhibition concentrations (MIC) obtained were 0.05 mg/ml and 0.4 mg/ml, 
respectively.  
2.3.4.4 Immunomodulating activity 
Otani & Maenishi184 reported that ovomucin enhanced the proliferation of 
mouse spleen lymphocytes, which were induced by lipopolysaccharide (LPS). 
Therefore, they supposed that ovomucin might be involved in the potential 
allergenicity to hen eggs. However, recent studies have shown that ovomucin is 
not very likely an egg allergen185.  
Thus, most likely the immunopotentiator activity of ovomucin is attributed 
to the bioactive properties of ovomucin, such as antitumour activity, as 
discussed above. Tanizaki et al.186 have reported that the glycopeptides of 
protease-digested ovomucin revealed strong macrophage-stimulating activity, 
and activated macrophages are known to secrete tumour necrosis factor-alpha 
(TNFα). The O-linked glycans were identified as active components.  
2.3.4.5 Antioxidant activity 
Boiled eggs were digested by pepsin and pancreatin, and thus the hydrolysate 
obtained was fractionated by using ion-exchange chromatograpy and RP-
HPLC187. Five fractions that contained the most potent antioxidant activities, as 
measured by ORAC, DPPH and ABTS methods, were further subjected to LC-
MS/MS analysis. A total of 63 peptides were identified, of which seven 
originated from β-ovomucin and four from α- ovomucin. Unfortunately, the 
antioxidant activities of individual peptides were not determined. 
In another study crude ovomucin obtained from whole EW by using the 2-
step IEP method was hydrolysed by Protamex, Flavourzyme or Alcalase188. 
The ABTS free radical scavenging activity for Protamex, Flavouzyme and 
Alcalase hydrolysate was 90.4%, 89.4% and 88.6%, respectively, compared to 
that of 17.3% for untreated ovomucin. The Protamex hydrolysate was further 
fractioned by using ultracentrifugal filtration and RP-HPLC. The fraction 
containing the highest antioxidant activity was subjected to MS analysis, and 
two peptides derived from α-subunit were identified with great accuracy. Both 
fragments, LDEPDPL (f686˗692) and NIQTDDFRT (f539˗549) were 
synthesized and antioxidant activities were measured to be 51.8 and 24.7% by 
DPPH assay.   
2.3.4.6 Hypocholesterolemic activity 
Nagaoka et al.189 reported that ovomucin inhibits cholesterol absorption in 
Caco-2 cells in vitro.  In addition, animal studies with male rats of the Wistar 
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strain fed the casein a diet showed that diet enriched with ovomucin 
significantly lowered both the serum total cholesterol and serum LDL + VLDL 
cholesterol level compared to rats fed the plain casein. Moreover, the total lipid 
concentration in liver was significantly lower in the ovomucin-enriched group 
compared to casein-fed rats. It was suggested that the hypocholesterolemic 
activity of ovomucin was in part due to the direct interaction of ovomucin and 
cholesterol-mixed micelles thus suppressing cholesterol absorption in jejunum.  
2.3.4.7 Dipeptyl dipeptidase-4 (DPP4) inhibitory activity 
It has been noted that hydrolysates of several EW proteins, including ovomucin, 
contained reasonable DPP4 inhibitory activity190. DPP4 is an enzyme, which 
has a substantial role e.g. in a glucose metabolism, as it is responsible for the 
degradation of glucagon-like peptide-1 (GLP-1). GLP-1 is an incretin hormone 
having antidiabetic action for example due to its ability to induce satiety and to 
stimulate insulin secretion and daily gastric emptying. DPP4 inhibitors are 
supposed to enhance the body’s own ability to control blood glucose level, thus 
being suitable for the treatment of type 2 diabetes191,192. 
2.4.4.8 Antihypertensive  activity 
Hypertension is one of the risk factors for cardiovascular disease193. 
Angiotensin-I Converting Enzyme (ACE) inhibitors are a group of medicines 
used for the treatment of hypertension, e.g. for lowering blood pressure194. Van 
Amerongen et al.195,196 presented an invention related to ACE inhibitory 
activity of various EW proteins. In vitro studies indicated that Alcalase-treated 
ovomucin had moderate ACE inhibition activity. In addition, it was reported 
that ovomucin-Alcalase hydrolysate demonstrated a significant blood pressure 
lowering effect in an in vivo test with spontaneously hypertensive rats.  
2.4  Summary of the literature review 
Ovomucin is a sulphated egg white glycoprotein, characterised by high 
molecular weight and a subunit structure. In addition to egg white, ovomucin is 
also found in chalazae and in the outer layer of the vitelline membrane. It is 
generally recognized that ovomucin consists of at least two subunits: α-
ovomucin (protein-rich subunit) and β-ovomucin (carbohydrate-rich subunit).  
The primary amino acid sequence of α-ovomucin has been reported to 
consist of 2,108 amino acids with a relative molecular mass of 233,553 Da. The 
estimated size of α-ovomucin could be calculated to be 256˗278 kDa, as the 
carbohydrate content of α-ovomucin has been reported to vary from 9.2% to 
15.5%. The main carbohydrates of α-ovomucin are mannose and N-
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glucosamine, which exist as N-glycan oligosaccharideshaving pentasaccharide 
core of GlcNAc2Man3 and a bisecting GlcNAc. 
Only a partial primary amino acid sequence of β-ovomucin has been 
revealed officially, consisting of 1,185 AAs with molecular mass of 132,217 
Da. The molecular weight of the β-ovomucin subunit has been estimated by 
SDS-PAGE or ultracentrifugation to be between 350 and 720 kDa. The 
carbohydrate content of β-ovomucin is very high: from 48% to 67%. These 
carbohydrates exist predominantly as O-glycosidically linked oligosaccharide 
moieties consisting of about 2˗6 carbohydrate units having both straight and 
branched chains also containing terminal sialic acid and ester sulphates. 
Moreover, two potential N-glycolysation sites have been identified in β-
ovomucin.  
Egg white contains two forms of ovomucin: insoluble and soluble ovomucin. 
Soluble ovomucin is presented both in thick and thin albumen, while insoluble 
ovomucin is found only in thick albumen. Insoluble ovomucin contains about 
2.5 times the β-ovomucin compared to that in soluble ovomucin. This 
abundance is attributed to a higher apparent viscosity of insoluble ovomucin to 
than that of soluble ovomucin. Similarly, the molecular weight of insoluble 
ovomucin is greater than that of soluble ovomucin.  
Ovomucin is most often isolated from egg albumen by using the isoelectric 
precipitation method. The crude ovomucin precipitate obtained by using the 
IEP method is highly insoluble in common buffer solutions, and can be 
solubilized completely as subunits with the buffers containing dissociating 
agents and reducing agents or by enzymatic hydrolysis as peptides. The 
advantages of the IEP method are that the method itself is very simple, cost-
effective and easy to up-scale. Alternatively ovomucin has been isolated from 
EW by using gel filtration chromatography. One advantage of the GFC method 
compared to IEP is that the separated ovomucin is usually very pure (= free of 
other egg white proteins) and already in soluble form. The main disadvantage 
is a low yield of ovomucin.  
Ovomucin is responsible for the gel-like properties of thick egg albumen. 
Although the occurrence of ovomucin-lysozyme interaction in egg white 
cannot be ruled out, it might be irrelevant for the gel-forming properties of 
ovomucin, as it has been noted that ovomucin is able to form a gel individually.  
Genetically, ovomucin belongs in the mucins. Ovomucin is encoded by two 
genes located on a locus on chromosome 5 in chicken. That locus is encoding 
gel-forming mucins and is quite similar to the corresponding human locus. The 
most significant difference is the presence of an additional gene in the chicken 
genome, an ovomucin gene, which encodes the α-ovomucin subunit. Moreover, 
it has been reported that β-ovomucin is the orthologue of human MUC6. 
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Also the biological role of ovomucin is considered to be the same as that of 
egg white; protection. The gel-like structure of thick egg white induced by 
ovomucin hinders the movement of micro-orgasms through to the albumen and 
also protects the developing embryo from impacts. In addition, ovomucin 
contains antimicrobial activity. Egg white thinning, the most important change 
in egg white during storage, is usually attributed to the degradation of the 
ovomucin complex. It has been reported that, during egg white thinning, β-
ovomucin is gradually dissociated and solubilized from the gel fraction of egg 
white to liquid fraction.  
Ovomucin has also been found to contain some techno-functional properties 
such as foaming and emulsification. In addition, ovomucin and ovomucin-
derived peptides have been reported to possess multiple bioactive properties. 
Ovomucin, therefore, seems to be a highly potential source of bioactive 
ingredients for novel functional foods or pharmaceuticals. 
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3  AIMS OF THE STUDY 
The objectives of the present study were: 
− to develop isolation methods for ovomucin (I-III) 
− to characterize ovomucin structure (I-III) 
− to compare various egg fractions as sources of ovomucin (II, III) 
− to study the effects of various dissolving methods for ovomucin (IV) 
− to investigate the bioactive properties of ovomucin and ovomucin-
derived peptides (III, IV) 
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4 MATERIALS AND METHODS 
4.1 Egg samples  
The shell eggs used in the studies (I˗III) were obtained from the local hen 
house (MTT Agrifood Research Finland, Animal Feeding Section. As of 1 
January 2015, MTT Agrifood Research Finland is part of Natural Resources 
Institute Finland [Luke]) or from a local store (III). The liquid egg white (II, 
IV) and the filtration by-product fraction (II) were obtained as a gift from 
Muna Foods Oy (former Munakunta, Piispanristi, Finland). Fraction II was 
obtained from an egg processing plant as e.g. chalazae were filtered off after 
egg breaking and yolk separation prior to further EW processing.  
 
 
 
Fig. 6 Fractionation of egg white layers. Figure is obtained from Publication III. 
4.2  Separation of egg white fractions  
The whole egg white fraction (II, III) was obtained by separating the albumen 
and yolk with a household yolk separator. Whole egg whites (chalaza cords 
removed by using tweezers) were pooled and homogenized with a household 
mixer at low speed so as to avoid foaming.  Thick egg white fraction (I, II) was 
separated by using a sieve (having a square aperture of 2.0 mm) according to 
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the modified method of Holst & Almquist197 and Brooks & Hale120. The 
separation of EW layers (III) was accomplished as shown in Figure 6.  
4.3  Isolation of ovomucin 
4.3.1  Isoelectric precipitation method (I˗IV) 
Crude ovomucin was isolated by using the isoelectric precipitation method 
described in Nakamura et al.198 with a few modifications. Briefly, homogenized 
albumen was diluted with three volumes of Milli-Q water, stirred for 10 (I) or 
30 (II) minutes by using a magnetic stirrer and then adjusted to pH 6 with 1 N 
HCl. The albumen dispersion was stirred for an additional 30 min (III) and 
then centrifuged (10,000  g, 10 min [I, II] or 20,000 × g, 20 min [III] at room 
temperature) to precipitate the crude ovomucin. The crude ovomucin 
precipitate was washed twice (I˗III) with Milli-Q water by centrifugation and 
then freeze-dried.    
Crude ovomucin for dissolving tests (IV) was prepared by using a 
combination of methods developed by Nakamura et al.198 and by Donovan et 
al.67 Liquid egg white was diluted with three volumes of de-ionized water, 
stirred for 30 minutes and then adjusted to pH 6 with 2 N HCl. After overnight 
settling, supernatant was siphoned off and the remaining suspension was 
collected and centrifuged (10,000  g, 20 min, RT) to precipitate crude 
ovomucin. The crude ovomucin precipitate was washed twice with water by 
centrifugation and then freeze-dried.  
4.3.2 Gel filtration chromatography (GFC) method (I, III) 
4.3.2.1 Preparative Sephacryl S-400 GFC with reducing agent (I) 
Gel filtration was performed with fast protein liquid chromatography (FPLC) 
system (GE Healthcare Life Sciences, Uppsala, Sweden) equipped with two 
Sephacyl S-400 HR columns (2.6 × 95 cm and 1.6 × 90 cm) connected in series. 
Ovomucin was dissolved in 150 mM imidazole-HCl buffer (pH 7.0) containing 
5% SDS and 1% β-mercaptoethanol.  
4.3.2.2 Preparative Superose 6 GFC with reducing agent (III) 
Preparative GFC was performed using an Äkta explorer system (GE Healthcare 
Life Sciences, Uppsala, Sweden) equipped with Superose 6 prep grade XK 
26/100 column (2.6 × 95 cm). Lyophilized IEP ovomucin was dissolved in 100 
mM of sodium phosphate buffer (pH 7.0) containing 5% SDS and 1% ß-
mercaptoethanol.  
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4.3.2.3 Preparative Superose 6 GFC without reducing agent (III) 
Preparative GFC was performed using an Äkta explorer system (GE Healthcare 
Life Sciences, Uppsala, Sweden) equipped with Superose 6 prep grade XK 
26/100 column (2.6 × 95 cm). IEP ovomucin precipitate (without lyophilisation) 
was dissolved in 100 mM of sodium phosphate buffer (pH 7.0) containing 5% 
SDS. 
4.4 Characterization of ovomucin 
4.4.1 Analytical GFC (II˗IV) 
Subunit profile and amounts of co-precipitated egg white proteins in crude 
ovomucin samples were determined with high-performance liquid 
chromatography (HPLC) equipped with two Superose 6 HR 10/30 gel filtration 
columns in series. Lyophilized IEP ovomucin was dissolved in 100 mM of 
sodium phosphate buffer (pH 7.0) containing 5% SDS and 1% ß-
mercaptoethanol. 
Standard curves (peak area vs. mg of protein) were created for each co-
precipitated egg white protein (ovotransferrin, ovalbumin, ovomucoid and 
lysozyme) by using commercial protein preparations. Ovalbumin (A-5503, 
purity 98%), ovotransferrin (C-0755, purity 80%), ovomucoid (Fluka 93621, 
purity 80%), and lysozyme (L-6876, purity 90%), were purchased from Sigma 
(St. Louis, MO, USA). The purity announced by the manufacturer for each 
protein was taken into account when generating standard curves. In Study II 
different ovomucoid was used (T-2011, purchased from Sigma, St. Louis, MO, 
USA). The purity was analysed by using GFC and found to be 99%.  
4.4.2 SDS-PAGE (I˗III) 
SDS-PAGE was performed by PhastSystem using PhastGel Gradient 4˗15-
minigels and PhastGel SDS Buffer Strips (GE Healthcare Life Sciences, 
Uppsala, Sweden). The Silver Stain SDS-PAGE Standards, High Range -kit 
(Bio-Rad Laboratories AB, Hercules, CA, USA) was used for molecular 
weight (MW) estimations.  
4.4.3 Amino acid analysis (I) 
Prior to amino acid analysis, the lyophilized crude ovomucin samples were 
freed from SDS by the ion-pair extraction method of Koningberg & 
Henderson199. Amino acids were analysed as phenylthiocarbamate (PITC) 
derivates by using HPLC200.  
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4.4.4 Carbohydrate analysis (II) 
Total hexose content was determined by a resorcinol sulphuric acid 
micromethod201. Ovomucin (2 mg) was hydrolyzed with 2 M HCl for 3 hr at 
95°C. Galactose was used as a standard. 
Total hexosamine was estimated by the 3-methyl-2-benzothiazoline 
hydrazone hydrochloride (MBTH) method using N-acetylglucosamine as a 
standard202. Each sample (2 mg) was hydrolyzed with 2 M HCl for 3 hr at 95°C. 
Sialic acid (N-acetylneuraminic acid, NANA) was determined by using the 
periodate-resorcinol method203. Ovomucin (2 mg) was hydrolyzed with 0.01 M 
HCl for 1 hr at 90°C. N-Acetylneuraminic acid was used as a standard. It is 
known that free sialic acids are destroyed during the hydrolysis step. In Study 
II this loss was measured to be 12%, which was then corrected to reported 
values. 
Standard curves (peak area vs. µg of carbohydrate) were created for each 
carbohydrate by using commercial preparations. Galactose (48259, purity ≥ 
99.5%), N-acetylglucosamine (01140, purity ≥ 99.0%) and sialic acid (01398, 
purity ≥ 99.0%) were purchased from Fluka (Buchs, Switzerland). 
4.5 Enzymatic hydrolysis of ovomucin (III, IV) 
Crude ovomucin dispersion was hydrolysed by trypsin (enzyme-substrate ratio 
[w/w] 1/100) at 45°C for 3 hr. The enzymatic reaction was terminated by 
heating (100°C/6 min). In all tests phosphate buffered saline (PBS, pH 7.4) and 
ovomucin concentration 0.2% (2 mg/ml) was used. After hydrolysis, the 
ovomucin sample was centrifuged (20,000 × g, 20 min) and aliquots of 
supernatant were taken for further analysis. 
4.6 Characterization of ovomucin hydrolysates (III, IV) 
Degree of hydrolysis (DH) was determined (III, IV) spectrophotometrically by 
measuring the number of -amino groups released during hydrolysis following 
reaction with -phthaldialdehyde by the method of Church et al.204 as modified 
by Frister et al.205.  
 
Relative solubility (RS) was calculated (III, IV) by using the following formula: 
 
RS ൌ 		 ୮୰୭୲ୣ୧୬	ୡ୭୬୲ୣ୬୲	ሺ୫୥ሻ	୭୤	୦୷ୢ୰୭୪୷ୱୣୢ	ୡ୰୳ୢୣ	୭୴୭୫୳ୡ୧୬	ୱୟ୫୮୪ୣ୵ୣ୧୥୦୲	ሺ୫୥ሻ	୭୤	ୡ୰୳ୢୣ	୭୴୭୫୳ୡ୧୬	୧୬	ୱୟ୫୮୪ୣ 	ൈ 100		
 
Materials and Methods 
 
 
39
Protein content of hydrolysed ovomucin sample was measured by using Bio-
Rad protein DC assay kit (Bio-Rad Laboratories Inc., Hercules, CA, USA).  
 
NANA content of hydrolysed ovomucin sample was measured (III, IV) as 
described in Chapter 4.4.4. 
 
Molecular weight estimations (III) of ovomucin hydrolysates were determined 
with high-performance liquid chromatography (HPLC) equipped with 
Superdex 200 HR 10/30 column (GE Healthcare Life Sciences, Uppsala, 
Sweden). The following standard proteins (Gel Filtration Standard, 151-1901, 
Bio-Rad, Hercules, CA, USA; MW in parentheses) were used in calibrating the 
Superdex 200 HR column for preparing standard curves for molecular weight 
estimation: thyroglobulin (670,000 Da), bovine gamma globulin (158,000 Da), 
chicken ovalbumin (44,000 Da), equine myoglobin (17,000 Da) and vitamin B-
12 (1,350 Da). Molecular mass distribution was calculated by dividing the total 
chromatogram area into three ranges of molecular mass (> 100 kDa, 100 – 10 
kDa, < 10 kDa) and expressed as a percentage of total area. 
 
Hemagglutination inhibition (HI) activity of ovomucin preparations was 
determined (III, IV) by using conventional method206. Briefly, various 
concentrations of PBS diluted ovomucin samples were mixed with a constant 
amount of virus suspension in microtitre plates. The mixture was incubated at 
22°C for one hour where after 1% chicken red blood cells were added. The 
plates were further incubated at 4°C and read after 30-40 min. HI activity was 
expressed as the minimal inhibition concentration (MIC) that was the highest 
dilution (µg/ml) of a sample protein that completely inhibited virus 
hemagglutination. 
4.7 Solubilisation of ovomucin (IV) 
In all the tests phosphate buffered saline (PBS, pH 7.4) and ovomucin 
concentration 0.2% (2 mg/ml) were used. After each dissolving test the 
ovomucin sample was centrifuged (20,000 × g, 20 min) and aliquots of 
supernatant were taken for further analysis. 
 
Conventional stirring. Ovomucin suspended in PBS was stirred (3 hr, RT) 
using a magnetic stirrer.  
 
Sonication. Ovomucin was dispersed in PBS and sonicated for 6 × 1 min or 12 
× 1 min at 80W (low) using LABSONIC 2000 Ultrasonic-Homogenizer 
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(B.Braun, Melsungen, Germany). During sonication, samples were kept in an 
ice-bath.  
 
Colloid milling. Ovomucin suspension was treated (16,000 RPM) for 1 min by 
using IKA magicLAB equipped colloid mill MK module (IKA WERKE Gmbh 
& Co., Staufen, Germany). 
 
Enzymatic hydrolysis. Described above (Chapter 4.5).   
 
Sonication + enzymatic hydrolysis. After 6 min sonication the ovomucin 
sample was hydrolysed by trypsin as described above. 
 
Colloid milling + enzymatic hydrolysis. Ovomucin suspended in PBS was 
treated both by colloid milling and by enzymatic hydrolysis in series. Both 
treatments were conducted as described above. 
4.8 Solubilisation rate of ovomucin (IV) 
Relative solubility (RS) was calculated by using the following formula: 
 
RS ൌ 	protein	content	ሺmgሻ	of	dissolved	crude	ovomucin	in	supernatant	ሺweight	ሺmgሻ	of	crude	ovomucin	in	sample	 ൈ 0.884ሻ 	ൈ 100 
 
Protein content of dissolved ovomucin sample was measured by using Bio-Rad 
protein DC assay kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). Factor 
0.884 is a protein content of crude ovomucin analysed by the Kjeldahl method. 
 
Ovomucin peak area (Area-%) was calculated by using the following formula: 
 
ܣݎ݁ܽ െ%	 ൌ 	 ܣݎ݁ܽሺݐሻܣݎ݁ܽሺ0ሻ 	ൈ 100		 
 
where Area(t) is the total peak area of dissolved ovomucin subunits after 
treatment, and Area(0) is the total peak area of crude ovomucin subunits 
sample (2 mg/ml) before treatment. Subunit profile and areas of ovomucin 
subunits were determined by using Superose 6 GFC method described by 
Hiidenhovi et al.II. 
 
NANA content of ovomucin sample was measured (III, IV) as in Chapter 4.4.4. 
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4.9 Yield determination of various ovomucin aggregates  
In this dissertation, the ovomucin precipitation obtained by IEP method is 
referred to as crude ovomucin. The protein composition of crude ovomucin 
was determined by GFC. Combination of the first three proteins (peaks 1-3, 
Figure 8) is called ovomucin-G, while the combination of β-ovomucin and α-
ovomucin (peaks 1-2, Figure 8) is called ovomucin-C. The yields for each 
ovomucin form were determined as described below. 
In addition it should be noted that the percentage amount of ovomucin-G 
(section 4.9.3) is the same as purity-% of crude ovomucin, a terminology used 
in paper I.     
4.9.1 Crude ovomucin (II˗IV) 
The freeze-dried ovomucin preparations were weighed, and these obtained 
weights were used to calculate the crude ovomucin contents of the albumen 
fractions in 100 g of albumen and as a percentage of total protein. The total 
protein content of the EW fractions was analysed by the Kjeldahl method using 
a conversion factor of 6.25. 
 
The amount of crude ovomucin (mg/100 g) was calculated by the following 
formula: 
 
Wሺcrudeሻ 	ൌ W1	W2 		ൈ 100		 
 
where W1 is the weight (mg) of the freeze-dried crude ovomucin precipitate, 
W2 is the weight (g) of the egg white used for crude ovomucin preparation  
4.9.2 Ovomucin-G (II˗IV) 
Amount of ovomucin-G (mg/100 g) was calculated by following formula: 
 
WሺOVMGሻ ൌ Wሺcrudeሻ ൈ 	OVMG%100 			 
 
where W(crude) was the weight (mg) of freeze-dried crude ovomucin per 100 g 
of EW. The percentage amount of ovomucin-G (OVMG%) was obtained from 
gel filtration data by subtracting the amounts of co-precipitating proteins 
(obtained by using standard curves) from the amount of crude ovomucin.    
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4.9.3 Ovomucin-C (III, IV) 
During the GFC analysis, a UV-detector (A280) measured only the protein 
concentration of eluated compounds. Because proteins eluated in the first three 
peaks are known to be glycoproteins, the peak areas of peaks 1, 2 and 3 were 
divided by 0.4, 0.85 and 0.88 respectively so as to take into account the amount 
of carbohydrate in each protein, as β-ovomucin, α-ovomucin and ovostatin 
were supposed to contain 60%, 15% and 12% of carbohydrate, respectively41,96. 
 
The amount of ovomucin–C (mg/100 g) was calculated by following formula: 
 
WሺOVMCሻ ൌ ൬ A1 ൅ A2A1 ൅ A2 ൅ 	A3൰ ൈWሺOVMGሻ 
 
where A1, A2 and A3 were corrected peak areas.
4.10 Statistical analysis (III, IV) 
The obtained data were subjected to analysis of variance using the general 
linear model procedure of SAS (SAS version 9.3, SAS Institute, Cary, NC, 
USA), and significant differences were determined using Duncan’s multiple 
range test (p < 0.05). 
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5 RESULTS AND DISCUSSION 
5.1 Isolation of ovomucin by using modified IEP method 
(I˗III)   
Figure 7 shows a schematic diagram of three IEP methods. Crude ovomucin 
was separated in studies I˗III by using a modified method (A) as described in 
Materials and Methods. The salt washing steps which are generally applied in 
IEP methods were omitted from this procedure for two reasons: firstly, to 
maximize the yield of ovomucin, and secondly, to keep the ovomucin 
separation procedure as simple as possible. Consequently, just two water 
washing steps were included in this purification protocol to remove only the 
major contaminants, thus leading to an ovomucin precipitate containing various 
amounts of other co-precipitated egg albumen proteins. Study II the purity of 
whole EW crude ovomucin was about 64% and the obtained ovomucin-G yield 
277 mg/100 g of whole EW. In addition, for thick EW crude ovomucin the 
corresponding values were 343 mg and ~65%.   
As a conventional method (B) the method described by Nakamura et al.198 is 
given here as an example (Figure 7). It has been reported in previous 
publications that, in order to achieve efficient removal of other co-precipitated 
albumen proteins, the ovomucin precipitate should be washed several times 
and/or kept in contact with water and KCl washing solutions for 24 hr per 
washing step80,83. Depending on the harshness of the washing procedure, one 
acquired purer ovomucin but simultaneously the yield was lower. Only 120 
mg/100 ml of thick EW ovomucin, corresponding to about 25% of the 
ovomucin present in thick albumen, was obtained after vigorous washing 
procedure80. 
The third method (C), 2-step method, first introduced by Omana & Wu24 
was reported to produce large quantities of ovomucin (over 400 mg/100 g of 
EW) with high purity. Figure 7C shows the original protocol, by which the 
ovomucin isolation took over two days. However, a method with reduced 
settling time from overnight to 2 h showed an almost equal yield and purity 
compared to original protocol24,28. Thus, crude ovomucin isolation was possible 
to complete within one day by using 2-step method. However, the salt removal, 
e.g. by dialysis, will take an additional day. Moreover, when the 2-step method 
was modified by adding a dialysis step, ovomucin-G yield has been reported to 
decrease to 208 mg88 or 214 mg/100 g of whole EW89. In the first case, the 
purity of crude ovomucin was about 89%. 
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As can be seen in Figure 7, modified IEP method (A) was much simpler 
compared both to conventional (B) and to the 2-step (C) method. In addition to 
simplicity, it was also faster, as the ovomucin separation was accomplished 
within hours, compared to 1˗2 days (including the dialysis step) needed when 
using two other methods. Also, the crude ovomucin yields obtained by using 
method (A) were somewhat higher.  
The main disadvantage was the lower purity of the crude ovomucin obtained. 
A preliminary study (Hiidenhovi et al.207, unpublished data), in which an 
additional salt washing step was included in method (A), has been conducted 
so as to overcome this problem. After the collection step, the crude ovomucin 
obtained was re-suspended in the concentrated (500 mM) salt solution, 
followed by the washing step as usual. The main impurities in the reference 
crude ovomucin were ovalbumin and lysozyme (Figure 8A). Each salt solution 
treatment reduced especially the amount of lysozyme in order, CaCl2 > NaCl 
~KCl (Figure 8 and Table 11). Due to this decrease in co-precipitated proteins, 
the purity-% of crude ovomucin (= a percentage of ovomucin-G) increased 
from 61% to 84% (Table 11). 
 
Table 11 Effect of salt on both crude ovomucin and ovomucin-G yield. 
Procedure Crude ovomucin  Ovomucin-G 
mg/100 g of 
egg white 
% of  
total protein
 mg/100 g of 
egg white 
% of total 
protein 
Ovomucin-G (%) 
(purity-%) 
Reference 525 ± 0a 4.5 ± 0.0a  322 ± 0a 2.8 ± 0.0a 61.4 ± 1.8b 
NaCl 350 ± 35b 3.0 ± 0.3b  274 ± 27ab 2.4 ± 0.2ab 78.5 ± 4.1a 
KCl 325 ± 36b 2.8 ± 0.2b  259 ± 29b 2.2 ± 0.2b 79.9 ± 1.1a 
CaCl2 212 ± 18c 1.8 ± 0.2c  178 ± 15c 1.5 ± 0.1c 84.0 ± 5.1a 
Given values are mean values and standard deviation of duplicate analyses. 
Dissimilar letters in the same column were significantly different (p < 0.05). 
It should be noted that, instead of a dialysis step for salt removal, salt-treated 
crude ovomucin precipitate was washed just twice with Milli-Q water by 
centrifugation and then freeze-dried. Unfortunately, due to the low amount of 
salt-treated crude ovomucin precipitates obtained, the ash content analysis to 
ensure the efficiency of salt removal could not be carried out. Therefore, a 
factor, which took account of the moisture and ash content in ovomucin 
precipitates, was estimated. These factors were 0.94, 0.94 and 0.90 for NaCl, 
KCl and CaCl2 treated ovomucin, respectively. Thus, especially in the case of 
CaCl2 a more efficient salt removal step might be convenient. Nevertheless, the 
yield of ovomucin-G varied from 178 mg to 274 mg after a salt treatment 
(Table 11). Hence, by using the IEP method (A) including additional salt 
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washing step, it was possible to produce comparable amounts of ovomucin 
with reasonable purity.  
 
Fig. 8 Superose 6 HR Gel filtration chromatogram of crude ovomucin prepared 
by the IEP method without and with the salt treatment step. Ovomucin isolation 
procedure: A = reference, B = 500 mM NaCl, C = 500mM KCl and D = 500 
mM CaCl2. Peak numbering: 1 = -ovomucin, 2 = -ovomucin, 3 = ovostatin, 
4 = ovotransferrin, 5 = ovalbumin, 6 = ovomucoid and 7 = lysozyme. Analysis 
conditions are described in Materials and Methods.   
As mentioned in Chapter 2.2, the low yield of ovomucin is the main 
disadvantage in the use of GFC for ovomucin isolation. An alternative protocol 
to increase the ovomucin yield obtained by GFC has been presented by 
Hiidenhovi et al.109, in which the modified IEP method (A) was used as a pre-
purification step and the crude ovomucin obtained was further dissolved into a 
PBS buffer and centrifuged. The insoluble materials were collected, and further 
analysed by using Superose 6 HR GFC. Analysis showed that this 
precipitatecontained (insoluble) ovomucin with a purity of 99%. The 
supernatant, containing dissolved ovomucin, was further concentrated by using 
membrane filtration with a 100 kDa cut-off. Besides increasing the ovomucin 
concentration, this step also reduced the amounts of co-precipitated EW 
proteins having MW’s less than 100 kDa. An aliquot of concentrated soluble 
ovomucin sample was loaded onto a preparative Sephacryl S-500 HR column. 
The proteins in the ovomucin sample were eluated in two peaks: A containing  
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Fig. 9 Elution profile of membrane filtration concentrated ovomucin sample 
obtained by preparative Sephacryl S-500 HR GFC. Peak A = ovomucin, and 
peak B = other egg white proteins. Thick line = collected fractions. Reprinted 
from Hiidenhovi et al. 2003109 with permission. 
 
 
 
Fig. 10 Elution profile of peak A obtained by Superose 6 HR 10/30 GFC. Peak 
1 = -ovomucin, peak 2 = -ovomucin, peak 3 = ovostatin, peak 5 = unknown 
(globulins?), and peak 7 = ovomucoid. Reprinted from Hiidenhovi et al. 
2003109 with permission. 
ovomucin and B containing other EW proteins (Figure 9). An aliquot of the 
pooled fractions corresponding to peak A was dialyzed against water, 
lyophilized, and weighed. Thus, it could be estimated that about 110 mg of the 
soluble ovomucin was purified in one GFC run. Moreover, analytical Superose 
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6 HR GFC revealed that the soluble ovomucin fraction appeared to be almost 
free of other EW proteins, and its purity was calculated to be 97% (Figure 10). 
The obtained ovomucin yield by using the IEP method (A) + GFC combination 
was remarkably higher compared to previously reported values, which were 
5˗10 mg per GFC run34,69. 
5.2  Characterization of ovomucin 
5.2.1 Subunit structure of ovomucin (I-III) 
In the studies (I˗III) ovomucin was isolated by using the IEP method, and the 
ovomucin precipitate obtained was referred to as crude ovomucin. The protein 
composition of the crude ovomucin was evaluated either by using preparative 
Sephacryl S-400 HR dual-column GFC (I) or by analytical Superose 6 HR 
dual-column GFC (II, III).  
 
 
 
 
Fig. 11 Elution profile of crude ovomucin obtained by Sephacryl S-400 HR 
GFC (A) and SDS-PAGE of pooled fractions from Sephacryl S-400 HR GFC. 
Analysis conditions are presented in Materials and Methods, and peak and lane 
numbering in Publication I. Reprinted and adapted with permission from 
Hiidenhovi et al. 1999. Copyright 1999 American Chemical Society.  
Sephacryl S-400 HR GFC separated crude ovomucin into eight peaks 
(Figure 11A). According to SDS-PAGE performed with EW protein standards, 
peak 6, 7 and 8 were identified as ovalbumin, ovotransferrin and lysozyme, 
respectively. Peak 1 could not be identified properly, and was suggested to be 
an unknown high MW ovomucin aggregate. In Study I, the identification of 
peaks 2˗5 was based both on amino acid composition analysis and on MW 
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estimation by SDS-PAGE (Figure 11B). Suggested identifications of peaks 2˗5 
are shown in Table 12. It should be noted that the SDS-PAGE results have also 
been re-calculated by using the same protocol as used in Study III.  
 
Fig. 12 Elution profile of crude ovomucin obtained by analytical (A) and by 
preparative (B) Superose 6 HR GFC with SDS-PAGE (C) of pooled ovomucin 
fractions purified by preparative GFC. Analysis conditions are presented in 
Materials and Methods, and peak and lane numbering in Publication III. Figure 
is obtained and adapted from Publication III. 
Due to long elution time (over 24 hr) of preparative Sephacryl 400 HR GFC, 
an analytical Superose 6 HR GFC method was developed in Study II that 
enabled crude ovomucin analysis in 3 hours. Superose 6 HR GFC separated 
crude ovomucin into seven peaks (Figure 12A). According to GFC performed 
with EW protein standards, peaks 4˗7 were identified as ovotransferrin, 
ovalbumin, ovomucoid and lysozyme, respectively. In Study III, the MWs of 
the main proteins eluting as peaks 1˗3 were estimated by using SDS-PAGE. In 
addition, the use of SDS-PAGE enabled the more precise examination of the 
purity of the peaks. In order to ensure sufficient material for the studies, a 
preparative Superose 6 GFC was used (Figure 12B). Fractions were collected 
and pooled from peaks 1˗3, and further analysed by SDS-PAGE (Figure 12C). 
Suggested identifications are shown in Table 13. 
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Table 12 Suggested identifications on proteins in peaks 2˗5 obtained by 
Sephacryl S-400 HR GFC including the corresponding band) appeared in SDS-
PAGE with estimated molecular weights (MW).  
Peak number 
(GFC) 
MW (kDa) 
(SDS-PGGE)* 
MW (kDa) 
(SDS-PAGE)** 
Suggested protein 
identification 
2 610 460 β-ovomucin 
3 350 320 α-ovomucin 
4 210 210 α-ovomucin 
5 160 160 ovostatin 
*determined by SDS-PGGE technique presented by Lambin et al.208 **re-
estimated by the protocol used in Study III. 
 
Table 13 Suggested identifications on proteins in peaks 1-3 obtained by 
Superose 6 HR GFC including the corresponding band(s) appeared in SDS-
PAGE with estimated molecular weights (MW).The main protein of each peak 
is shown in bold.  
Peak number * 
(GFC) 
Band number 
(SDS-PAGE) 
MW (kDa) 
 
Suggested protein 
identification 
1 1 370 β-ovomucin 
2 2 290 α-ovomucin 
2 3 220 α-ovomucin 
3 4 150 ovostatin 
3 5 120 α/β-ovomucin 
 
In Study II, peaks 1, 2 and 3 obtained by Superose 6 HR GFC were called β-, 
α2- and α1-ovomucin, respectively, according to nomenclature presented by 
Itoh et al.11 However, the results shown both in Table 12 and 13 indicate that, 
at least with fresh eggs, the main proteins in SDS-PAGE gel regions 
approximately 350˗400, 200˗280 and 150˗180 kDa are β-ovomucin, α-
ovomucin and ovostatin, respectively. In addition, both studies (I and III) 
suggested an existence of another α-subunit in gel region around 300 kDa. The 
MW difference between the proteins in peaks 3 and 4 (Table 12) and in bands 
2 and 3 (Table 13) might be caused by a different degree of glycosylation 
between these two proteins. On the other hand, some previous studies indicate 
self-association of -ovomucin in dilute salt solutions21,33.   
Besides ovostatin (150 kDa band), peak 3 contained also another protein 
with an estimated MW of 120 kDa (band 5, Figure 12C). Also Hammershøj et 
al.23 have reported a protein with the same order of magnitude (122 kDa) in 
SDS-PAGE pattern of crude ovomucin, and suggested that it could be α1-
ovomucin. Furthermore, Hayakawa & Sato33 reported that the sonicated α-
ovomucin treated with mercaptoethanol appeared as a slight diffuse band in the 
region around 100 kDa in SDS-PAGE (Weber-Osborn protocol). However, it 
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has been reported that proteolytic degradation of reduced and alkylated β-
ovomucin indicated the presence of 112˗120 kDa fragment.27,58,174 Although 
quite likely, this 120 kDa-fragment was orientated from ovomucin, and more 
specific analytical methods, such as MS, are needed to precise identification. 
Because in previous studies ovomucin yields have been calculated for 
ovomucins consisting of both two and three subunits, the following 
nomenclature is used in this study: the combination of the first three proteins 
(peaks 1˗3, Figure 12A, corresponding β-ovomucin, α-ovomucin and 
ovostatin/ovomucin) is called ovomucin gel (ovomucin-G), while the 
combination of β-ovomucin and α-ovomucin (peaks 1˗2, Figure 12A) is called 
ovomucin complex (ovomucin-C) to facilitate comparison of previous data 
with present results (Table 14˗19). 
5.2.2 Subunit structure of ovomucin-G (III) 
Heterogeneous behaviour, e.g. the existence of three compounds, has been 
noted during sedimentation velocity measurements of ovomucin31,59,60. In Study 
III, the composition of crude ovomucin was studied more closely. Crude 
ovomucin was dissolved into a buffer that contained SDS but no reducing 
agents, and introduced into a preparative Superose 6 HR column. Elution was  
also performed without reducing agents. It was noted that a high molecular 
weight protein was eluted as a single peak well ahead of other EW proteins 
(Figure 13). Pooled fractions, collected from the middle of this peak and 
further reduced by using β-mercaptoethanol, were subjected to SDS-PAGE 
analysis, which separated it into three bands. The MWs of these bands were 
estimated to be 370, 220 and 160 kDa, which corresponded to β-ovomucin, α-
ovomucin and ovostatin, respectively, as discussed above (Chapter 5.2.1). Thus, 
it seems quite likely that ovostatin is somehow associated with β- and α-
ovomucin. This possible interaction might even have some effect on the 
physical nature of various EW layers, as the amount of ovostatin varied from 
30 to 370 mg per 100 g of EW (Table 19). This interaction might be 
accomplished by electrostatic forces or by hydrogen bonds, as after the severe 
washing procedure, only β-ovomucin and α-ovomucin were detected in SDS-
PAGE27. Clearly, the role of ovostatin in the ovomucin gel forming process 
might be worth investigating more closely.   
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Fig. 13 Elution profile of crude ovomucin obtained by GFC without reducing 
agents (A) and SDS-PAGE of reduced ovomucin samples (B). Lane 1 = 
molecular weight markers, lane 2 = injected crude ovomucin sample, lane 3 = 
ovomucin fraction (1+1 with SDS-PAGE sample buffer), lane 4 = ovomucin 
fraction (reduced in elution buffer). OVT = ovotransferrin, OVA = ovalbumin, 
OMUC = ovomucoid and LYZ = lysozyme. Figure is obtained from 
Publication III. 
5.3 Eggs as source of ovomucin (II, III) 
Two studies (II and III) were conducted in which various egg fractions were 
investigated as a source of ovomucin to find the most relevant fraction for 
value-added utilization of ovomucin. In Study II, both shell egg and industrial 
EW fractions were compared. Whole EW was used as a reference, and thick 
EW was chosen because many studies linked to ovomucin’s bioactive 
properties have been carried out with ovomucin isolated from thick EW. 
Similarly, two industrial EW fractions were used: liquid EW, a pasteurized EW 
product, and a filtration by-product fraction. The latter fraction was obtained 
from the egg processing plant as e.g. chalazae were filtered off after egg 
breaking and yolk separation prior to further EW processing.  
In Study III, EW was fractioned into four basic EW layers, outer thin white, 
thick white, inner thin white, and chalaziferous layer (including chalazae). In 
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addition, the thick EW layer was further divided into a gel and a liquid fraction. 
Thus, altogether six “natural” fractions were compared.  
It should be noted that, in order to make the results of these studies more 
comparable, the GFC results of Study II were re-integrated. In addition, in this 
dissertation the by-product results are presented as a daily base in contrast to 
the original paper (II), where they were presented as a united one. This 
separation also enabled the demonstration of possible differences between 
consecutive days. 
5.3.1 Protein composition of crude ovomucin  
Protein compositions of crude ovomucins obtained in Study II are shown in 
Table 14. The highest percentage amount of ovomucin-G was found to be in 
the liquid EW (about 71%), while in the other fractions it was practically equal 
but lower (63˗65%). Naturally, this variation was linked to other co-
precipitated egg white proteins. The main impurities in the crude ovomucins 
were ovalbumin and lysozyme, which was consistent with previous studies23-25. 
However, there was not such a considerable variation in percentage amount of 
lysozyme between different EW fractions, as was noted in Study III (Table 15). 
Interestingly, there was no variation between protein compositions of by-
product ovomucins between two consecutive days. However, a longer follow-
up time is needed for precise conclusions.   
Protein compositions of crude ovomucins obtained from various EW layers 
are presented in Table 15. To our knowledge, this was the first time as the 
protein profiles of crude ovomucins obtained from these six egg white layers 
were presented simultaneously, facilitating the comparison of ovomucins 
obtained from different egg white layers. As expected, the percentage amount 
of ovomucin-G (OVMG%) varied among the EW layers. Interestingly, OVMG% 
was highest in outer thin EW crude ovomucin. Moreover, OVMG% of liquid 
thick EW was higher than in the gel fraction and equal into the chalaziferous 
fraction. Thus, the share of ovomucin-G in various crude ovomucins was 
highest in most liquid egg white fractions. In Study III, especially the amount 
of lysozyme varied considerably between EW layers. For example, thick white 
crude ovomucin contained about 2.5 times the amount of lysozyme compared 
to outer thin white crude ovomucin. It has been reported that lysozyme 
interaction with β-ovomucin is more extensive than with α-ovomucin90. 
However, this possible interaction did not solely explain the difference noticed, 
since, even though gel fraction contained about twice the amount of β-
ovomucin compared to liquid fraction, the amount of lysozyme was quite the 
same in both fractions (Table 15 and 19). Similar behaviour also existed 
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among EW fractions in Study II, e.g. whole EW vs. filtration by-product (day 2) 
fraction (Table 14 and 16).  
Ovomucin–lysozyme interaction is mainly considered to be electrostatic, 
although some hydrophobic and hydrogen interactions also exists36,82,90,93,94. 
The protein-protein interactions are known to be influenced by pH, salt type 
and salt concentration209. Thus, the action of various cations might also cause 
this observed difference. Actually, Robinson91 has reported that Ca2+ and Mg2+ 
inhibited ovomucin-lysozyme interaction. Therefore, in the future, it might be 
advantageous also to measure the concentrations of several cations, especially 
divalent ones, in the four basic EW layers.  
5.3.2 Various complex forms of ovomucin  
The amounts of different ovomucin aggregates, namely crude ovomucin, 
ovomucin-G and ovomucin-C, are shown in Table 16 and 17. In Study II the 
amounts obtained for thick EW crude ovomucin, ovomucin-G, and ovomucin-
C were about 530, 340 and 310 mg, while in Study III the corresponding 
values were about 570, 330 and 280 mg/100 g of EW (Table 16 and 17), 
respectively. In addition, when crude ovomucin, ovomucin-G and ovomucin-C 
was presented as a percentage of total protein corresponding values were for 
Study II 5.3%, 3.4% and 3.1%, and in Study III 5.7%, 3.3% and 2.8%, 
respectively. These results were surprisingly similar, as samples were obtained 
from different eggs, and moreover, there was a gap of many years between 
analyses. Thus, the IEP method (A) seems to be quite reliable and repeatable. 
In Study II, both shell eggs and industrial EW fractions were studied. 
Despite the complex form of ovomucin, industrial fractions contained more 
ovomucin than shell egg fractions (Table 16). Three EW fractions containing 
most of the ovomucin were: filtration by-product (day 2) > liquid EW > 
filtration by-product (day 1). Thus, for now in the case of filtration by-product 
there was also statistically significant difference between the dates of collection. 
The results of Study III are shown in Table 17. There were large differences 
in the amounts of various ovomucin complex forms among the EW layers, but 
more or less the order was about the same despite the ovomucin form. The 
three most ovomucin-rich fractions were: the chalaziferous layer > the gel 
fraction of the thick EW layer > the thick EW layer. Actually both the 
chalaziferous layer and the gel fraction contained more ovomucin than 
filtration by-product (day 2) fraction.  
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5.3.3 Ovomucin subunits  
The percentage distribution of ovomucin subunits both for ovomucin-G and for 
ovomucin-C is shown in Table 18 and 19, in addition the amount (mg/100 g of 
EW fraction) of each subunit protein in various egg white layers. Respectively, 
Table 3 summarizes the previous data of the relative content of α– and β-
ovomucins in ovomucin complexes obtained from various EW layers.  These 
values agreed quite well with results obtained in Study III for subunit 
distribution of ovomucin-C (Table 19). Thus ovomucin-C equates well with 
earlier models for ovomucin structure, which was thought to consisting of two 
subunit, namely α-ovomucin and β-ovomucin20,21,33,42-46. On that basis, it is 
reasonable to assume that the subunit protein distribution presented for various 
ovomucin-G forms (Table 18 and 19) is also equally plausible.   
One aim of these studies (II, III) was to compare different egg white 
fractions as sources of ovomucin. Especially, the amount of β-ovomucin was 
very interesting, as many of the bioactive properties of ovomucin are linked to 
β-ovomucin. In both studies (II, III), the same three fractions that contained 
most of ovomucin also contained the largest amounts of β-ovomucin. In the 
study II the order was: filtration by-product (day 2) > filtration by-product (day 
1) > liquid EW, and in Study III it was: gel fraction of thick EW layer ~ 
chalaziferous layer > thick EW layer.  
Although filtration by-product fraction seemed to be a very prominent 
source of β-ovomucin, process development has reduced its amount so 
significantly that it has no practical meaning any more. Similarly, the amount 
of the chalaziferous layer is so low that it has only academical interest. The 
production of the gel fraction of thick EW on a larger scale is possible, but in 
doing this one should find some use for the thin EW fractions. Thus, the 
commercial liquid EW fraction seemed to be the best option, especially if it 
generally contains as high an amounts of β-ovomucin as was found in Study II.  
5.4 Dissolving of ovomucin (IV) 
5.4.1  Dissolving of ovomucin by using physical methods  
The effects of various physical methods for crude ovomucin solubilisation are 
demonstrated in Table 20 and Figure 14. The lowest solubility was achieved 
after conventional stirring (3 hours) regardless of the method used for 
measuring. However, RS-value for stirring seemed to be too high (about 49%), 
without statistically significant difference between stirring and colloid milling. 
As can be seen in Figure 13A, during conventional stirring mainly the co-
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precipitated EW proteins are dissolved into PBS. Both Area-% and NANA 
values obtained for the conventional stirring fraction were lower compared to 
other crude ovomucins (Table 20), indicating a lower amount of solubilized 
ovomucin. In all other cases, the difference was statistically significant between 
stirring and other dissolving methods. Thus, it was quite obvious that, if the 
solubility measuring method of crude ovomucin is based only on protein 
determination, it will produce results that are too high in some cases.  Similar 
results have been reported by Hammershøj et al.23. They noted that solubility of 
“unwashed” ovomucin, which contained co-precipitated EW proteins as 
impurities, into deionised water was about 30% compared to 10% obtained for 
“washed” ovomucin.  
 
Table 20 The effect of various physical methods to crude ovomucin solubility.  
Treatment RS (%) Area-% (%) NANA (µg/ml) 
Stirring (3 hr) 49.1 ± 1.8c 19.2  ± 1.5d   5.6 ± 0.6c 
Colloid milling (1 min) 49.6 ± 3.6c 31.1  ± 1.3c 16.1 ± 1.0b 
Sonication (6 min) 60.8 ± 3.6b 47.1  ± 1.5b 19.1 ± 0.7b 
Sonication (12 min) 79.5 ± 2.4a 68.0  ± 12.1a 26.9 ± 3.0a 
Given values are mean values and standard deviation of triplicate analyses. 
Dissimilar letters in the same column were significantly different (p < 0.05). 
Colloid milling is commonly used to produce dispersion and to homogenise 
mixtures. In Study IV, a milk-like, smooth and opaque crude ovomucin 
suspension was attained by using IKA colloid mill. This “high-speed mixing” 
favoured ovomucin dissolution into PBS compared to conventional stirring 
(Table 20 and Figure 13A and 13B). Thus, much more ovomucin was 
dissolved in just 1 min by using colloid milling compared to 3 hours of stirring. 
A higher solubilisation rate was achieved by using both sonication 
treatments compared to colloid milling. However, it should be noted that the 
treatment times used for sonication were higher, 6 and 12 minutes, compared to 
1 minute of colloid milling. Nevertheless, in Study IV the highest solubilisation 
rate by using various physical treatments was obtained with 12-minutes 
sonication. The longer sonication time clearly enhanced solubilisation of crude 
ovomucin into PBS. Thus, sonication seemed to be a time-dependent 
phenomenon that was in accordance with a previous study44, in which the MW 
of ovomucin was found to decrease in the course of time. 
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Fig. 14 Elution profiles of degraded ovomucins obtained by Superose 6 HR 
gel-filtration chromatography. A = conventional stirring, B = colloid milling, C 
= sonication (6 min), D = sonication (12 min). Peak numbering: 1 = -
ovomucin, 2 = 1-ovomucin, 3 = ovostatin, 4 = ovotransferrin, 5 = ovalbumin, 
6 = ovomucoid and 7 = lysozyme.  Figure is obtained from Publication IV. 
 
Table 21 Percentage protein distribution of ovomucin-G.  
 
 
 
 
 
 
 
 
 
 
Given values are mean values and standard deviation of six analyses (*n = 5, 
**n = 3). Dissimilar letters in the same column were significantly different     
(p < 0.05). 
The effect of dissolving methods investigated on the percentage distribution 
of ovomucin-G subunits is shown in Table 21. The subunit distribution of 
ovomucin–G after sonication (both 6 and 12 minutes) and conventional stirring 
were quite similar, and resembled that of reference crude ovomucin, as no 
statistical difference between these treatments were noted. In contrast, colloid 
milling seemed to enhance β-ovomucin dissolution into PBS. 
Egg white layer Protein distribution of ovomucin-G 
 β-ovomucin 
(%) 
α-ovomucin 
(%) 
ovostatin 
(%) 
Stirring (3 hr) 17.6 ± 3.0b 48.8 ± 5.9a 33.6 ± 4.4a 
Colloid milling (1 min)* 23.2 ± 1.2a 47.6 ± 3.3a 29.3 ± 3.3b 
Sonication (6 min) 18.0 ± 3.0b 45.8 ± 2.4a 36.2 ± 2.4a 
Sonication (12 min) 16.7 ± 3.7b 50.4 ± 3.2a 32.9 ± 1.7ab 
    
Reference ovomucin ** 17.9 ± 0.7b 49.2± 0.7a 32.9 ± 0.3ab 
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5.4.2  Dissolving of ovomucin by using enzymatic hydrolysis  
Enzymatic hydrolysis is commonly used to enhance ovomucin solubility into 
conventional buffers23,52,81,87,104-107. In Study IV, trypsin was used both alone 
and in combination with some physical dissolving methods. In each case, DH 
values obtained were quite low due to a low E/S-ratio (1/100) (Table 22). In 
addition, hydrolysis temperature was a little higher (45°C) than normally used 
(37-40°C) for trypsin. In comparison, a DH value of 11% was reached already 
after 2 hours of trypsin hydrolysis when E/S=1/25 and 40°C was used87. 
Nevertheless, trypsin treatment seemed to enhance the ovomucin solubilisation 
attained by physical methods. For example, after 3 hours of enzymatic 
hydrolysis the NANA content was 20.7 µg/ml, compared to 5.6 µg/ml obtained 
by 3 hours of stirring (Table 22). Similarly, enzymatic hydrolysis enhanced 
ovomucin solubilisation both after 6 min of sonication and after colloid milling 
(Table 21 and 22). Actually, the NANA-content 28.8 µg/ml after a 
combination method of sonication plus hydrolysis was the highest value 
attained in Study IV.   
 
Table 22 The effect of enzymatic hydrolysis to crude ovomucin solubility. 
Treatment DH (%) RS (%) NANA (µg/ml) 
Stirring (3 hr) nd 49.1 ± 1.8c    5.6 ± 0.6d  
Enzymatic hydrolysis (3 hr) 3.7 ± 0.1b   62.9 ± 8.4b 20.7 ± 1.2c 
Sonication (6 min) + enzymatic hydrolysis* 5.5 ± 0.8a  76.1 ± 2.1a 28.8 ± 1.4a 
Colloid milling + enzymatic hydrolysis 3.0 ± 0.3b 61.6 ± 4.0b 25.8 ± 1.2b 
Given values are mean values and standard deviation of triplicate analyses. 
*RS and NANA (n = 2). nd = not determined. Dissimilar letters in the same 
column were significantly different (p < 0.05). 
In another study (Hiidenhovi et al.87), 10 different enzymes were compared 
for their efficiency to hydrolyse ovomucin. Additionally, the effect of different 
enzyme and substrate concentrations on enzymatic hydrolysis of ovomucin was 
studied in more detail using three enzymes (Pronase, Proteinase K, and 
Trypsin). All 10 enzymes had a significant effect on ovomucin solubility. 
Pronase and Proteinase K were the most efficient of all 10 enzymes, whereas 
Trypsin and Pepsin were the most efficient among the food-grade enzymes. 
Enzyme concentration was found to affect the composition of the obtained 
ovomucin hydrolysates. Interestingly, with Pronase, we found considerable 
variation in the amount of peptides having a MW > 100 kDa when the enzyme 
concentration was changed from 0.1 to 2%, even though the RS of both 
hydrolysates was in the same range. The RS of hydrolyzed ovomucin decreased 
as the substrate concentration increased from 5 to 20 mg/ml (E/S = 1%), 
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whereas it had virtually no effect on DH values. Thus, it was possible to 
produce ovomucin hydrolysates with very different peptide compositions, not 
only by using different enzymes but also by changing the hydrolysis conditions. 
These results can be used to produce ovomucin hydrolysates having different 
biological activities. 
5.5 Antiviral properties of ovomucin  
5.5.1 Antiviral properties of crude ovomucins obtained from 
various EW layers (III) 
In Study III, the crude ovomucins obtained from various EW layers were 
treated by trypsin to obtain antiviral peptides. Under rather mild hydrolysis 
conditions, E/S = 1% and hydrolysis time of 3 hrs, the degradation of various 
crude ovomucins was rather limited. The DH was about 4˗6% for all the other 
egg fractions, except for liquid fraction, for which it was little over 10% (Table 
23). The relative solubility was also quite low: the variation being from 45% to 
65%. The highest RS values were found to be in crude ovomucins, in which β-
ovomucin content was least, namely outer thin and liquid fraction of thick EW. 
About 40˗65% of dissolved peptides were found to still have MW over 100 
kDa indicating the presence of ovomucin fragments in hydrolysates.  
Only three hydrolysed ovomucin fractions were found to contain HI activity 
against NDV, namely thick EW, inner thin EW and gel fraction of thick EW 
(Table 23). Interestingly Tsuge et al.172 have reported that the MIC value for 
trypsin-treated thick white ovomucin was equally 46 µg/ml. However, it should 
be noted that the observed MIC values cannot be compared straightforwardly, 
because the virus concentration used by Tsuge et al.172 was not given. 
Moreover, both thick EW and gel fraction ovomucin showed HI activity 
against avian influenza virus (AIV) subtype H5. In addition, gel fraction 
ovomucin inhibited also AIV subtype H7. All three ovomucin hydrolysates 
having HI activity also contained the highest amount of NANA (Table 23) the 
difference being statistically significant. Thus, quite likely NANA residues of 
the β-ovomucin have similar ability to bind also to AIV as to NDV173,210.  
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However, the low NANA content in chalaziferous layer hydrolysate, as well 
as the absence of HI activity, was unexpected, as the crude ovomucin isolated 
from chalaziferous layer contained the highest amount of β-ovomucin (about 
160 mg/100 g of EW, Table 19). The mild hydrolysis conditions used in Study 
III were probably inadequate to degrade the chalaza layer ovomucin properly. 
Most likely, this inadequacy was caused by the structural difference of the 
chalaza cords (tight bundle of strands) compared to other EW layers (viscous 
liquids or gels). Moreover, the hydrolysed ovomucin samples were kept frozen 
for several months, and that might also have a negative effect on HI activity.   
5.5.2 Effects of various dissolving methods on antiviral properties 
of ovomucin (IV) 
Table 24 Hemagglutination inhibition activity of different ovomucin samples. 
Given values are mean values and standard deviation of triplicate analyses. 
MIC = minimal inhibition concentration, NDV= Newcastle disease virus, AIV5 
= avian influenza virus, subtype H5, AIV7 = avian influenza virus, subtype H7, 
n.i. = no inhibition *n = 2. 
The solubilized ovomucin fractions obtained in Study IV were further tested 
for HI activity. As can be seen in Table 24, only three dissolving protocols 
tested produced moderate antiviral activity against NDV, namely colloid 
milling, enzymatic hydrolysis and a combination of sonication and enzymatic 
hydrolysis. Moreover, trypsin-digested crude ovomucin was found to have 
antiviral activity (MIC being approx. 77 µg/ml) against avian influenza virus, 
both subtype H5 and subtype H7 (Table 24).   
It has been shown that the NANA residue in the β-ovomucin contributed 
greatly to the binding of ovomucin to various viruses, such as NDV and 
AIV173,177,210. Therefore, it was not surprising that HI activity was not found 
after conventional stirring, due to the minimal solubility of ovomucin achieved 
by this method. Instead, the lack of HI activity after both sonication treatments 
was strange. Especially in the case of 12-minute sonication, as the sonicated 
ovomucin contained about twice the amount of NANA found in the colloid 
                                                                          
Treatment 
MIC  (µg/ml) 
NDV AIV5 AIV7 
Stirring (3 hr) n.i. n.i. n.i. 
Sonication (6 min) n.i. n.i. n.i. 
Sonication (12 min) n.i. n.i. n.i. 
Colloid milling (1 min) 122 ± 9 n.i. n.i. 
Enzymatic hydrolysis (3 hr) 154 ± 21 77 ± 10 77 ± 10 
Sonication (6 min) + enzymatic hydrolysis* 186 ± 5 n.i. n.i. 
Colloid milling + enzymatic hydrolysis n.i. n.i. n.i. 
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milling sample, the latter fraction was still the active one, having HI activity 
against NDV (Table 21 and 24). Due the large amount of bound-NANA in 12 
minute-sonicated ovomucin fraction, the reason for the lack of HI activity 
might be some kind of, as yet unknown, structural modification during 
sonication. In addition to NANA residue, also the amino acid sequence seems 
to be important for interaction with both viruses and for inhibition the 
propagation of both NDV and AIV211-213.   
Colloid milling was the only physical treatment that induced HI activity 
alone. Strangely, this HI activity was lost after enzymatic hydrolysis, while the 
other enzymatically hydrolysed fractions were found to have HI activity (Table 
24). Unfortunately, these above-mentioned deviations might also be caused by 
some kind of problems, e.g. in sample solubility, when frozen samples were 
reconstituted into HI analysis. Another cause might be prolonged storage of 
IEP ovomucin in the refrigerator before lyophilisation.  
 
Table 25 Effect of various enzymes and hydrolysis time on crude ovomucin 
solubility and HI activity. 
Enzyme RS (%) DH (%)  MIC µg/ml)  
   NDV AIV5 AIV7 
Alcalase (3h) 73 ± 3b 5.3 ± 0.6bc   45 ± 2.0e 22 ± 1.0c   22 ± 1.0d 
Alcalase (24h) 72 ± 5b 5.7 ± 0.04bc 176 ± 11.2a 44 ± 2.8a   88 ± 5.6b 
      
Esperase (3h) 36 ± 0e 2.2 ± 0.3d 117 ± 0.0b 22 ± 0.0c   88 ± 0.0b 
Esperase (24h) 46 ± 1d 2.9 ± 0.1d   56 ± 0.8d 28 ± 0.4b 112 ± 1.7a 
      
Neutrase (3h) 58 ± 3c 4.5 ± 0.6c   71 ± 3.9c 18 ± 1.0d   35 ± 2,0c 
Neutrase (24h) 75 ± 1b 5.9 ± 0.6b   46 ± 0.7de 23 ± 0.3c   23 ± 0.3d 
      
Protamex (3h) 85 ± 2a 6.0 ± 0.5b   52 ± 1.1de 13 ± 0.3e   13 ± 0.3e 
Protamex (24h) 75 ± 2d 8.6 ± 0.9a   46 ± 1.1de 11 ± 0.3e   11 ± 0.3e 
Given values are mean values and standard deviation of duplicate analyses. 
Dissimilar letters in the same column were significantly different (p < 0.05). 
The latter cause might be the most probable explanation, as another 
experiment (IV) was conducted, in which the effect of enzymatic hydrolysis on 
HI activity was investigated by using several enzymes. The EW and the crude 
IEP ovomucin before and after hydrolysis were frozen as before, but the 
storage time was much shorter compared the one used in dissolving test (IV). 
Moreover, the E/S ratio was a little higher (2%) compared to dissolving test, 
but without any prominent effect to DH or RS. As shown in Table 25, much 
higher HI activities were obtained this time. The effect of longer hydrolysis 
time (24 hours) varied among enzymes used, but generally there was no need 
for longer hydrolysis time meaning lower process costs.  
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Both Newcastle disease and avian influenza are pathogenic, thus causing 
substantial loss to the poultry industry. In addition, there is still a great concern 
that highly pathogenic, avian influenza virus (H5N1 or bird flu virus), with a 
mortality rate over 60% mutate so as to adapt to humans210,214. The controlling 
of AIV infection in poultry is crucial to prevent its outbreak among humans215. 
Thus, any possible compound that has the ability to inhibit propagation of AIV 
(or NDV), such as ovomucin, is worthy of further investigation. 
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6 SUMMARY AND CONCLUSION 
A simple and rapid IEP method for crude ovomucin isolated was developed. 
By using this method, ovomucin separation was accomplished within hours, 
compared to the 1˗2 days (including the dialysis step) needed when using 
several other methods. The main disadvantage was the low purity (about 
60˗65%) of obtained crude ovomucin. However, by using the IEP method 
including the additional salt washing step, it was possible to produce 
comparable amounts of ovomucin with reasonable purity 
Structural characterization revealed that ovomucin is composed of two 
subunits, α- and β-ovomucin, as egg white protein formerly called α1-
ovomucin seemed to be ovostatin. However, ovostatin tends to elute with both 
α- and β-ovomucin as a single peak in non-reducing GFC. Therefore, it might 
be quite possible that ovostatin is associated within β- and α-ovomucin. This 
interaction could even have some effect on the physical nature of various EW 
layers, as the ovostatin content varied a great deal, up to ten times, between 
different egg white layers. Thus, in future, the role of ovostatin in the ovomucin 
gel-forming process might be worth to investigating more closely. In addition, 
there was some evidence of self-association of -ovomucin. 
Various EW fractions were compared as a source of ovomucin. Although 
filtration by-product fraction was a very prominent source of both crude and β-
ovomucin, process development has reduced its production so significantly that 
it has no practical meaning any more. Similarly, while the chalaziferous layer is 
an ovomucin-rich fraction, the actual amount of this EW layer is so low that it 
has only academic interest. The isolation of the gel fraction of thick EW on a 
larger scale is possible, but simultaneously one should also find some use for 
thin EW fractions. Thus, the commercial liquid egg white is possible the best 
option, especially if it generally contains as large an amounts of β-ovomucin as 
was found in these studies.  
Crude ovomucin was dissolved both by using physical and enzymic methods. 
Of the physical methods, sonication was the most effective in dissolving 
ovomucin, but colloid milling seemed to be a very promising alternative. A 
milk-like, smooth and opaque crude ovomucin suspension was attained by 
using colloid mill. In addition, this method is easily up-scaled.  
The dissolved ovomucin fractions were further tested for HI activity, and 
three dissolving protocols tested produced antiviral activity against NDV, 
namely colloid milling, enzymatic hydrolysis and a combination of sonication 
and enzymatic hydrolysis. Interestingly, trypsin-digested crude ovomucin was 
found to have antiviral activity against avian influenza virus: both subtype H5 
and subtype H7.  
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